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Background− Accumulation of transformation related protein 53 (p53), apoptotic cell death 
and rarefication of myocardial angiogenesis may be involved in the development of cardiac 
dysfunction during chronic pressure overload.  
 
Objective− The aim of this study was to determine whether prevention of endothelial cell 
apoptosis deletion of p53 in endothelial cells improves cardiac remodeling during pressure 
overload and prevents the transition from hypertrophy to heart failure. 
 
Methods and Results− Mice with endothelial deletion of p53 (End.p53-KO) were generated 
by crossing p53fl/fl mice with mice expressing Cre recombinase under control of an inducible 
Tie2 promoter. Cardiac hypertrophy was induced by transverse aortic constriction. Serial 
echocardiography measurements revealed improved cardiac function and survival in 
End.p53-KO mice. In End.p53-WT controls, cardiac hypertrophy was associated with 
increased p53 levels, whereas banded hearts of End.p53-KO mice exhibited lower apoptotic 
cell numbers, both in endothelial and non-endothelial cells. Moreover, a higher cardiac 
capillary density, improved perfusion and elevated Hif1 and Vegf protein levels were 
observed, and inhibition or deletion of p53 also promoted endothelial sprouting in vitro and 
new vessel formation following hindlimb ischemia in vivo. Hearts of End.p53-KO mice 
exhibited markedly less interstitial fibrosis compared to End.p53-WT controls, and lower 
mRNA levels of p53-regulated genes involved in extracellular matrix production and 
turnover, or transcription factors involved in endothelial-to-mesenchymal transition.  
 
Conclusions− Our data suggest that accumulation of p53 in endothelial cells contributes to 
cardiac apoptosis, blood vessel rarefication and fibrosis during chronic pressure overload and 
support the essential role of endothelial cells and cardiac angiogenesis for preserving 












1.1. Cardiac Hypertrophy and Heart Failure 
 
The term “hypertrophy” is derived from the Greek word hyper (increased growth) and trophe 
(diet or nutrition).
1
 Cardiac hypertrophy (CH) is the thickening of the heart muscle 
(myocardium), which may result in the decrease in size of the left and right ventricle, but 
later also is associated with chamber dilation and cardiac enlargement. Heart failure (HF) is 
the incapability of the heart to sufficiently pump blood in response to the systemic needs. HF 
may be induced by a number of common disease stimuli, including long-standing 
hypertension, aortic stenosis, or familial hypertrophic and dilated cardiomyopathy, but also 
myocardial infarction associated with coronary artery disease.
2
 Cardiac hypertrophy and 
failure occur as a result of a combination of genetic, physiologic and environmental factors.
3
 
In the absence of external stimuli such as increased afterload or a partial loss of tissue due to 
infarction, the myocardial size and function in the adult heart remain stable. When such 
conditions arise, the heart undergoes chamber enlargement and myocyte hypertrophy to adapt 
to the increased hemodynamic demands.
4
 This adaptive response of the heart to chronically 
increased afterload may fail if continued over the long term, resulting in the development of 
tissue ischemia, ventricular dilation and cardiac dysfunction. Like Neil Young said: ''The 




1.1.1. Morphologic Classification of Cardiac Hypertrophy 
 
Three stages of hypertrophic transformation of the heart were defined in the 1960s by 
Meerson and colleagues:
6
 (1) developing hypertrophy, which is excessive output load, (2) 
compensatory hypertrophy, in which the workload/mass ratio is normalized and resting 
cardiac output is maintained, and (3) heart failure with ventricular dilation/ 
dysfunction. Characteristically, two different types of hypertrophic phenotypes can be 
distingued, as shown in Figure 1.1: Physiological hypertrophy and pathological hypertrophy. 
Pathological hypertrophy is again divided into two types: a) concentric hypertrophy or 
compensatory hypertrophy due to pressure overload, which is characterized by parallel 
addition of sarcomeres and lateral growth of individual cardiomyocytes, and b) eccentric 
hypertrophy due to volume overload, which is characterized by addition of sarcomeres in 
16 
 
series and longitudinal cell growth.
1;7
 Physiological and pathological hypertrophy differ both 




(Figure and part of legend adapted from Maillet M et al. Nature Reviews  
Molecular Cell Biology 2013;14: 38-48) 
 
Figure 1.1. The heart has the ability to increase its size and, depending on the stimulus, this results in 
physiological or pathological hypertrophy. Hypertrophy decreases ventricular wall stress by increasing the 
thickness of the wall. It follows Laplace's law, which says wall stress (or tension) is an inverse function of wall 
thickness (tension = (pressure × radius)/(2 × wall thickness)). Cardiac hypertrophy can be either eccentric or 
concentric growth based on the geometries of the heart, and individual non-pathological eccentric hypertrophy is 
characterized by an increase in ventricular volume with a coordinated growth in wall and septal thicknesses, 
where individual cardiomyocytes grow in both length and width. However, eccentric hypertrophy under 
pathological conditions (myocardial infarction or dilated cardiomyopathy) can lead to wall dilation with 
preferential lengthening of cardiomyocytes. Physiological stimulation can also induce a less pronounced form of 
eccentric hypertrophy. Concentric hypertrophy is characterized by a reduction in left ventricular chamber 
dimension and an increase in free wall and septal thicknesses, and individual cardiomyocytes typically increase 
in thickness more than in length (resulting in a decreased length/width ratio). Concentric hypertrophy usually 
arises owing to pathological conditions such as chronic hypertension or valvular stenosis. Isometric exercise 
training, such as wrestling or weight-lifting, also induces a milder form of concentric cardiac hypertrophy that is 
not known to be pathological. The heart can go from a normal state to a state of physiological hypertrophy and 




1.1.2. Physiological Hypertrophy 
 
Physiological hypertrophy is an adaptive response to intermittent cardiac pressure and 
volume overload due to chronic exercise training, such as long distance running or 
swimming, or during pregnancy. In athletes and physically active persons, cardiac 
hypertrophy generally develops as an adaptive response to a physiological process which 
does not cause or lead to heart failure. However, in 20% of deconditioned athletes, 
ventricular dilation does not completely reverse to normal even after 5 years suggesting that 




The best example of physiological hypertrophy is postprandial cardiac hypertrophy in 
Burmese pythons, in which oxygen consumption increased sevenfold and ventricular mass 
increased significantly by 40% while digesting rats equal to 25% of body mass after 48 hrs of 
fasting. This increase was fully reversible, and the ventricular mass returned to its fasting 
mass in post-digestion animals after 28 hrs.
11;12
 Few reports showed that humans also 
undergo postprandial cardiac hypertrophy. Also during pregnancy, cardiac output increases to 
match placental blood flow, resulting in a physiological hypertrophy due to continuous 
volume overload. The heart undergoes modest eccentric cardiac hypertrophy and recovers 
fully to normal size of the heart after the delivery.
13;14
 In few cases, some of patients after 




1.1.3. Pathological Hypertrophy 
 
Pathological hypertrophy develops in response to mechanical stress induced by either 
extrinsic factors, such as increased pressure or volume overload in hypertension and valvular 
diseases, or intrinsic factors, such as ischemia-induced cardiac remodeling, which leads to 
contractile dysfunction and heart failure.
1;7
 In contrast to physiological hypertrophy, 
pathological hypertrophy is associated with a loss of myocytes, fibrotic replacement (cardiac 
fibrosis) and cardiac dysfunction, and an increased risk of heart failure and sudden death. 
 
During the initial stages of hypertrophy, the heart undergoes compensated growth to maintain 
cardiovascular function by cardiac myocyte enlargement and normalizing ventricle wall 
stress by formation of new sarcomeres. At later stages, the function of the hypertrophied heart 
18 
 
ultimately decompensates leading to left ventricle dilation and heart failure (figure 1.2). The 
causes underlying this final decompensation are not completely understood. 
 
 
(Picture and legend adapted from Frey N et al. Circulation 2004;109:1580-1589) 
 
Figure 1.2. Physiological Versus Pathological Hypertrophy: Physiological hypertrophy is an adaptive 
response to growth signals. Pathological hypertrophy develops in response to stress signals. It is not known 
whether stress signals are unique or whether overstimulation (“too much of a good thing”) evokes a pathological 
response. Similarly, it is not known whether physiological versus pathological hypertrophy derives from 
activation of unique “beneficial” signaling cascades or whether extreme activation of these same pathways 
evokes a pathological response. MI indicates myocardial infarction. 
 
1.1.4. Cardiac Hypertrophy Marker 
 
At the molecular level, cardiac hypertrophy is associated with increased expression of fetal 
genes and classical hypertrophic markers such as ANP, BNP, the β-isoform of myosin heavy 
chain (β-MHC)
16
, or the α-skeletal muscle isoform of actin (αSA).
7
 In addition, several 
studies on cardiac hypertrophy or heart failure have shown decreased expression of the 
calcium cycling protein SERCA2a.
17
 In general, ANP and BNP mRNA levels tend to be 
increased in “ailing” hearts, i.e. those with reduced ventricular ejection or in heart failure 
with or without hypertrophy. Similarly, increased αSA and decreased SERCA mRNA levels 
19 
 
are observed in hypertrophy models that progress towards heart failure. In contrast, β-MHC 
has been increased in several hypertrophy models with normal cardiac and cardiomyocyte 




Recent studies have used microarrays to perform global, unbiased comparisons of regulated 
genes in physiological and pathological hypertrophy. Kong et al.
18
 compared transcript 
profiles in control rats (inactive Dahl salt-sensitive rats (Dahl/SS rat) on low-salt diet), 
physiologically hypertrophied rats (every day exercise), and compensated pathological 
hypertrophy (Dahl/SS rat on high-salt diet) using Affymetrix Rat Genome microarrays. 
Prolonged high-salt diet resulted in progression to heart failure, providing a fourth group 





(Figure adapted from Bernardo B C et al. Pharmacology & Therapeutics 2010;128:191-227)  
 
Figure 1.3. Venn diagram depicting shared and distinct gene cluster expression profiles of physiological 
and pathological hypertrophy. HSF1 is a heat shock protein transcription factor that has recently been shown 




In physiological hypertrophy, the genes largely regulated were representing metabolism and 
cellular growth, including members of the IGF/epidermal growth factor signaling pathway. In 
contrast, genes identified with pathological hypertrophy were largely from inflammation and 
stress-response clusters, and the genes expressed in decompensated hypertrophy/heart failure 
included apoptotic factors as shown in figure 1.3.  
 
In addition to the above microarray data, clinical as well as experimental evidence suggests 
that the rarefication of cardiac capillaries promotes tissue hypoxia, cell death and replacement 
20 
 
fibrosis and contributes to the progression from compensated hypertrophy to contractile 




Angiogenesis plays an important role during the progression of adaptive cardiac hypertrophy. 
Inhibition of angiogenesis leads to decreased capillary density, which can hinder the cardiac 
growth and ultimately affect the adaptive hypertrophy to contractile dysfunction
24
. Therefore, 
angiogenesis plays a vital role in coordinating tissue growth with enough blood vessels to 
maintain cardiac function, and disruption of this coordination between angiogenesis and 
tissue growth in the heart may promote the transition from adaptive cardiac hypertrophy to 
heart failure.
24
 Induction of angiogenesis can also increase the cardiac mass without an 
external stimulus and cardiac function in Myocardial Infarction (MI) condition.
25
 Induction of 
angiogenesis by coexpressing VEGF and angiopoietin-1 has been shown to improve 




1.2. New Vessel Formation 
 
Endothelial cells receive multiple signals from their environment that eventually stimulates 
them to form new vessels. The development of new vessels can be considered in several 
different contexts. The two major processes responsible for the development of new blood 
vessels are “Vasculogenesis” and “Angiogenesis”.  
 
Vasculogenesis is the formation of blood vessels from endothelial progenitors or angioblasts 
in situ.
31
 This is the mechanism by which the primitive vascular plexus is formed.
32
 
Vasculogenesis occurs in various steps starting with the generation of angioblasts from 
mesoderm; second is the assembly of angioblasts into vascular structures; third is the 
formation of a vascular lumen and finally, organization of continuous vascular networks. 
Blood vessels formed by the process of vasculogenesis are immature, that means they are not 




Angiogenesis is the progression of vascular growth by sprouting, bridging, and extension of 
capillaries from pre-existing blood vessels.
34-37
 In contrast to vasculogenesis, angiogenesis 
involves vascular growth and maturation. The angiogenesis process starts with the proteolytic 
degradation of interstitial tissue and the basal membrane of the parental vessel and 
21 
 
endothelial cells migrate, proliferate, avoid apoptosis and finally differentiate into new 




Most of the normal tissues in the adult have a low rate of cell turnover, with an exception of 
the epithelial tissues and the hematopoietic elements in the bone marrow. Smooth muscle and 
endothelial cells of the blood vessel have a turnover time of many months. Only 0.01% of all 
endothelial cells of a normal adult are dividing at any given moment. However, in response to 
angiogenic stimulation, endothelial cells enter into an actively proliferating state to form new 
blood vessels.
40




(Figure and legend modified from: Yoo SY et al. Mediators Inflamm 2013;2013:127170) 
 
Figure 1.4. Processes in angiogenesis. (1) Angiogenic factors bind to their receptors on endothelial cells and 
activate signal transduction pathways. (2) Degradation of the extracellular matrix. (3) Endothelial cells migrate 
out of the preexisting capillary wall and proliferate. (4) Integrins are expressed by endothelial cells, thus 
facilitating their adhesion to the extracellular matrix and their migration for tube formation. (5) Angiopoietin-1 
binds to Tie-2 receptors and stimulates pericyte recruitment and vessel stabilization. 
 
Extracellular signals involved in these processes are mainly secreted factors that act in a 
paracrine fashion. Specialized receptors like G-protein-coupled receptors, tyrosine kinase 
receptors, tyrosine-kinase associated receptors and serine-threonine kinase receptors are the 
main transmembrane receptors that transduce angiogenic signals. The pathways of signal 
22 
 
transduction between the surface receptors and the final effectors of the modified endothelial 
cell behavior are partly known.  
 
1.2.1. Vascular Endothelial Growth Factors and Receptors 
 
Vascular endothelial growth factor-A (also called VEGF) is the master regulator of 
angiogenesis and vascular permeability, as it is required to initiate the formation of immature 




After the discovery of VEGF-A, 4 other members in the human VEGF family have been 
identified: VEGF-B, VEGF-C (also called VEGF-2), VEGF-D, placental growth factor 
(PlGF). Recently an entirely unrelated family of growth factors known as the angiopoietins 
(Ang) and particular members of the very large ephrin family have been identified as having 
unique effects on the endothelium. 
27;46;47
 As said earlier, VEGF is required to initiate the 
formation of immature vessels by vasculogenesis or angiogenic sprouting. Ang1 and 
ephrinB2 are required for further remodeling and maturation of this immature vasculature, 
particularly as endothelial cells integrate with supporting cells such as smooth muscle cells 
and pericytes. Following vessel maturation, Ang1 continues to be important for maintaining 
the quiescence and stability of the mature vasculature.
48
 The downstream signals of VEGFs 
in the vascular endothelium are mediated by 3 tyrosine kinase signaling receptors (VEGF 





(Figure adapted from Rahimi N. Mol Cancer Ther 2012;11:538-48) 
 
Figure 1.5. VEGF super family ligands and receptors. A schematic of VEGF ligands and their interactions 
with VEGF receptors. 
 
Hypoxia-inducible factors (HIFs) are oxygen sensitive transcription factors, which regulate 
the expression of hypoxia-inducible genes (e.g. VEGF) at lower oxygen concentrations. 
Stabilization of HIF1α activates the transcription of genes that participate in key mechanisms 
involved in enhancing tissue perfusion and oxygenation, such as angiogenesis, cell 
differentiation, anaerobic metabolism, and apoptosis.
49
 HIF1α plays an important role in 





(Figure adapted and modified from Rahimi N. Mol Cancer Ther 2012;11:538-48) 
 




1.2.2. Angiogenesis Stimulators and Inhibitors 
 
Angiogenesis is considered to depend on the balance between endogenous stimulators and 
inhibitors.
52
 Recent studies suggests that endothelial cell apoptosis plays an important role to 
maintain or fix damaged blood vessels during angiogenesis.
53
 There are several enhancers/ 
stimulators of endothelial survival including VEGF,
28;54;55
 basic Fibroblast Growth Factor 
(bFGF),
56
 integrins (e.g. αvβ3),
57-60
 Nitric Oxide (NO),
61
 platelet-derived growth factor, HIF-
1α, as well as angiogenic oncogenes, such as Ras, and tumor suppressors, such as p53.
62
 





 Tumor Necrosis Factor (TNF),
67
 Transforming Growth Factor-β (TGF-β),
68
 
and many more. Endogenous inhibitors of angiogenesis include various antiangiogenic 
peptides, hormone metabolites, and apoptosis modulators. Some of the above listed inhibitors 





(Figure adapted from Nyberg P et al. Cancer Res 2005;65:3967-79.) 
 





Cardiac hypertrophy initially promotes adaptive angiogenesis by HIF1α-dependent induction 
of pro-angiogenic factors. By this, the heart maintains its compensatory state during pressure 
overload but, in long term, can lead to hypertension.
70
 p53 is upregulated during hypertrophy 
and inhibits the protective pro-angiogenic activity of HIF1α, eventually leading to heart 
failure. A central role of cardiac endothelial cells and angiogenesis is supported by findings 
that inhibition of new blood vessel formation or inadequate angiogenesis during the 
development of cardiac hypertrophy is the main reason for that the adaptive cardiac 
hypertrophy transmits the development of left ventricular (LV) dysfunction and ultimately 
heart failure.
71;72
 Whereas stimulation of angiogenesis by increasing the production and 
secretion of angiogenic growth factors, such as VEGF, in the hypertrophied heart improves 
cardiac function and delays the onset of heart failure.
25;29;73
 In recent years, a number of 
publications have revealed the anti-angiogenic properties of p53.
74-79
 However, the molecular 
mechanisms involved in the regulation of cardiac angiogenesis and in particular, the role of 
p53 in the reduction of cardiac vessel density during pathological hypertrophy are 
incompletely understood.  
 
1.3. Tumor Suppressor Protein p53 in Angiogenesis and Heart Failure 
 
p53 is a tumor suppressor protein with proapoptotic and antiproliferative activities. p53 
transcriptionally activates variety of molecules or genes that induce apoptosis, cell growth 
arrest, inhibit angiogenesis, functions in DNA repair, regulate senescence and others (figure 
1.8). p53 is upregulated in adaption to harmful stimuli, including hypoxia, oxidative stress, 
UV damage or infections. In the cardiovascular system, p53 plays a crucial role in 
development of heart failure.  
 
For example, elevated levels of p53 were reported in myocardial biopsies of patients with 
heart disease
80
 and found to progressively increase with disease severity.
81
 Increased 
apoptotic cell numbers have also been described in rodents following transverse aortic 
constriction (TAC),
82
 a model frequently used to study the cellular and molecular changes 
during cardiac hypertrophy and failure.
83
 Puma (p53-upregulated modulator of apoptosis) 
inactivation may serve as a preferential target to prevent heart failure induced by cellular 
stress.
84
 Supporting a causal role of apoptotic cell death and p53 in the development of heart 





 whereas p53 activation accelerates LV function deterioration.
87
 Disruption of p53 
activation in adipose tissue attenuated inflammation and improved insulin resistance but also 
ameliorated cardiac dysfunction induced by chronic pressure overload.
88
 In contrast, recent 
studies showed that in radiation therapy, p53 functions in endothelial cells to protect mice 
from myocardial injury induced by whole heart irradiation.
89
 p53 induces connective tissue 
growth factor (CTGF) expression and promotes liver fibrosis, suggesting that the p53/CTGF 




In addition to its role as master regulator of cellular senescence, cell cycle arrest and 
apoptosis, p53 is involved in the transcriptional regulation of genes controlling diverse 
biological processes, such as differentiation, migration or angiogenesis.
91 
P53 plays as 
antiangiogenic by transcriptionally activating the α (II) collagen prolyl-4-hydroxylase gene, 
resulting in the extracellular release of antiangiogenic fragments of collagen type4 and 18.
92
 
However, the role of endothelial p53 expression for the cardiac response to chronic pressure 




(Figure adapted from Christopher J et al. Nature Reviews Cancer 2009; 9, 862-873) 
 
Figure 1.8. The p53 pathway. P53 is at the centre of a complex web of biological interactions that 
translates stress signals into cell cycle arrest, apoptosis and prevention of angiogenesis. MDM2 and 
MDM4 proteins bind to p53 in non-stressed conditions and ubiquitylate p53 and target it for degradation 




1.4. Cardiac Fibrosis 
 
Cardiac fibrosis (CF) is characterized by the accumulation of extracellular matrix (ECM) 
proteins in the cardiac interstitial spaces, and contributes to both systolic and diastolic 
dysfunction in many cardiac pathophysiological conditions.
93
 CF is a major determinant of 
cardiac function and contractility. CF leads to distorted organ structure which is often 
observed in patients with advanced heart failure.
94
 CF increases myocardial stiffness and 
induces electrical heterogeneity, leading to systolic and diastolic dysfunction and sudden 
death.  
 
Cardiac fibroblasts are activated by a variety of pathological stimuli, thereby undergoing 
proliferation, differentiation to (myo-)fibroblasts, and production of various cytokines and 
ECM proteins within the heart.
95;96
 The interactions of myocytes, ECM, and cardiac 
fibroblasts controls physiological cardiac function.
97
 Cardiac fibroblasts maintain ECM 
homeostasis to facilitate proper cardiac contraction.
98
 Fibroblasts regulate cardiomyocyte 
function by secreting various growth factors
99
 and via direct cell–cell interactions.
100
 They 
are crucial for angiogenesis and vascular homeostasis in the heart.
101 
Based on the 
morphological appearance fibroblasts are classified as inactive or active fibroblasts. The 
active fibroblasts appear to be large and produce more collagen leading to cardiac fibrosis.
102
 
Fibrosis occurs in two forms, reactive interstitial fibrosis or replacement fibrosis.
103;104
 
Reactive interstitial fibrosis is observed in left ventricular pressure overloading models which 
progresses without loss of cardiomyocytes. This initial reactive interstitial fibrosis, which is 
an adaptive mechanism, will progress into replacement fibrosis, characterized by 




1.4.1. The Origin of Cardiac Fibroblasts during Embryonic Development 
 
The actual number of fibroblasts in the cardiac tissue remains unknown. It has been known 
that the adult mouse heart contains approximately 55% myocytes and only 45% non-myocyte 
cells (~27% fibroblasts). But, the adult rat heart consists of 30% myocyte cells and 70% non-
myocyte cells (~67% fibroblasts).
104;106;107
 Because of distinct origins, cardiac fibroblast is an 
extremely heterogenic cell population. Cardiac fibroblasts can be derived either from 1) 
epithelial–mesenchymal transition (EMT)
108





 under the influence of growth factors, 2) resident fibroblasts, 3) cardiac 
endothelium via endothelial-mesenchymal transition (EndMT) or bone marrow-derived 





(Figure adapted from Kalluri R and Weinberg RA, J Clin Invest 2010;120:1786) 
 
Figure 1.9. Origin and sources of fibroblasts during organ fibrosis. Four possible mechanisms are depicted. 
One study suggests that about 12% of fibroblasts are from bone marrow, about 30% can arise via local EMT 
involving tubular epithelial cells under inflammatory stress, and about 35% are from EndMT, the remaining 
percentage likely emerge via proliferation of the resident fibroblasts and other still unidentified sources. 
 
1.4.2. Endothelial-to-Mesenchymal Transition (EndMT) 
 
EndMT is a complex biological process in which endothelial cells under the pressure of pro-
fibrotic stimuli (e.g. TGFβ and hypoxia) acquire a mesenchymal or myofibroblastic 
phenotype with the expression of mesenchymal cell products such as α-SMA, vimentin or 




In cardiac fibrosis, about 30% of activated fibroblasts are generated from endothelial cells via 
a cellular phenotype switch which is referred to as endothelial-mesenchymal transition 
(EndMT)
112
. Upon phenotypic change these cells resemble as fibroblasts and leave the 
29 
 
microvascular bed and enter the interstitium. Hence, EndMT contributes to cardiac fibrosis 





(Picture adapted from Arciniegas E et al. Am J Physiol Lung Cell Mol Physiol 2007; 293:L1-L8) 
 
Figure 1.10. Schematic diagram illustrating potential mechanisms involved in endothelial-mesenchymal 
transition. Many initiating factors, which can lead to loss of cell-cell contacts, have been described. These 
factors are capable of activating metalloproteinase and serine protease family members and are important in loss 
of cell-cell contact. Interruption of cell-cell or cell-matrix contact, activates transcription factors, which are 
actively involved in suppression of E-cadherins and other endothelial-specific proteins. Upregulation of a 
mesenchymal gene program follows. Importantly, in some situations, this process may be reversible. HGF, 
hepatocyte growth factor; BMP, bone morphogenetic protein; TGF, transforming growth factor; MMPs, matrix 
metalloproteinases. 
 
Recent in vivo evidence using an endothelial lineage tracing approach suggested that a 
substantial number of cardiac fibroblasts are derived from resident endothelial cells, which 
have undergone endothelial-to-mesenchymal transition (EndMT) in response to transforming 
growth factor (TGF)-β.
112;113
 Although an association between endothelial cell apoptosis and 
EndMT has been suggested,
114





1.5. Hypothesis and Study Objective 
 
The tumor suppressor protein p53 is proapoptotic in function, and a number of recent data 
have shown that p53 is upregulated during heart failure. In this study we hypothesized that in 
response to cellular stress, p53 undergoes stabilization and promotes apoptosis of endothelial 
cells, leading to decrease in capillary density in the heart, thereby increasing hypoxia and 
promoting to cell death and fibrosis. Hence, in this study, we would like to examine whether 
deletion of the p53 in endothelial cells is able to preserve the cardiac microvasculature, to 
prevent pathological cardiac remodeling and the development of fibrosis in response to 






2. Materials and Methods 
 
2.1. Laboratory Equipment 
 
0.22 μm filter unit, Millex-GS Millipore (GLGS0250S) 
ART-MICRA D-1, No 30072, homogeniser 
Autoclave, Tuttnauer 5075 ELV, Biomedis 
BANDELIN SONOPULS sonicator 
Biosafety cabinet with aspirator for tissue culture, CA/RE5, W. Krannich 
Capillary tips, 200µl, #728204, Biozym Scientific GmbH 
Chemical fume hood, Norddeutsche Laborbau 
CO2 incubator, SANYO, W. Krannich 
CODA™ Monitor, Kent scientific corporation 
DNA electrophoresis set, Bio-Rad 
Drying oven, Heraeus 
Eppendorf centrifuge 5415D  
Eppendorf centrifuge 5810R 
Eppendorf mastercycler gradient 
FACS 5 ml polystyrene round-bottom tube, 12 X 75 mm, BD Falcon 
FACSAria II cell sorter, BD Bioscience 
FACSVantage SE system, BD Biosciences 
Fluorescence microscope (AXIO ZEISS) coupled to a digital camera  
Freezing container Nalgene Labware (5100-0001) 
Gel photo printer, SEIKO Precision DVP-1200, Biozym 
Glass Pasteur pipettes, 230 mm 
Injection needle 0.6 X 30 mm, 23G ¼”-Nr.14 
iQ™5 Multicolor Real Time PCR Detection system, BIO-RAD 
Labcycler, Sensoquest, Biotechnica 
Laminar flow hood with a HEPA filter 
Microscope coverglasses, 18 X18 mm, Gerhard Menzel GmbH 
Microscope glass slides, Gerhard Menzel GmbH  




Mini Trans-Blot® Cell, Serial No. 37S/5986 
Mini-PROTEAN Precast Gels 
Mini-PROTEAN® 3 Cell, Serial No. 67S/12383 
MiniVent, mouse ventillator, Type: 845, Hugo Sachs Electronics 
MultiImage light cabinet, Alpha Innotech Corporaton 
Multi-micropipette, Eppendorf AG 
NanoDrop
® 
ND-1000 Spectrophotometers, Thermo Scientific 
PERIMED, Periscan PIM 3 
Pipette tips for volumes 0.1-1000 µl  
Pipettes for volumes 0.1-1000 µl 
Power Pac 200, BIO-RAD 
Protran BA 85, 0.45µm, Whatman™ GE Healthcare 
Reaction tubes (1.5 and 2 ml) 
Reaction tubes (15 and 50 ml) 
Slide storage boxes 
Standard plastic pipettes (2, 5, 10, 25 ml) 
Syringe, Omnifix 40 Solo, 1ml/40 I.U. B.Braun (for matrigel injection) 
Upright microscope for fluorescence or DIC microscopy, Olympus BX51 
Vortex-Genie 2, Schuett Labortechnik 
Water bath set at 37°C 


















Supplier Cat. Number 
0.5M EDTA, pH 8.0 Ambion  AM9260G 
1M Tris pH 7.0  Ambion  AM9851 
1M Tris pH 8.0  Ambion  AM9856 
2-Mercaptoethanol BIO-RAD 161-0710 
2-Propanol Sigma 278475 
2X Laemmli Sample Buffer BIO-RAD 161-0737 
5M NaCl  Ambion AM9760G 
Acetic acid 96% Carl Roth T179.2 
Acetone Merck 8.222.511.000 
Antibody Diluent Dako S-3022 
Biozym LE Agarose  Biozym  840004 




Ethanol absolute for analysis Merck 1.00983.1011 
FITC-Griffonia (Bandeiraea)  
Simplicifolia lectin I, Isolectin B4 
Vector  FL-1201 
FITC-Griffonia lectin I Vector FL-1101 
Hydrochloric acid (HCl) 37% Fluka/Sigma 84422 
Ketamin 10% Medistar 13690.00.00 
Mayer’s hematoxylin  Sigma MHS32 
Methanol J.T.Baker 8402 
Mounting medium  Vector H-1000 
Paraformaldehyde (PFA) Sigma P6148 
PCR nucleotide mix Promega C114H 
Pierce®BCA Protein Assay Reagent A Thermo Scientific 23228 
Pierce®BCA Protein Assay Reagent B Thermo Scientific 1859078 
Ponceau S solution Sigma P7170-1L 
Proteinase K, recombinant PCR Grade Roche 3115828001 
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RNaseZap  Ambion  AM9780 
Rotiphorese® Gel 30 (37,5:1) Roth  3029.1 
SDS 20% Solution  Ambion  AM9820 
Sodium Chloride (NaCl),0.9% Braun 6697366.00.00 
Sodium Hydroxide (NaOH), 2N Merck 1.091.361.000 
SuperSignal® West Pico  
Chemiluminescent Substrate 
Thermo Scientific 34080 
Triton X-100 Fluka/Sigma 93426 
TWEEN
® 
20  Sigma  P1379 
Xylariem(Xylazine) Riemser 400177.00.00 






Company Cat. Number 
FITC Annexin V Apoptosis  
Detection Kit I 
 








































2.4. Buffers and Solutions 
 
10X PBS 80 g NaCl, 2 g KCl, 14.4 g Na2HPO4 and 2.4 g KH2PO4 
in 800 ml ddH2O. Adjust pH to 7.4 with HCl. Make up 
the final volume to 1 liter and sterilize by autoclave. 
 
10X TBS 24.2 g Tris Base, 80 g NaCl in 800 ml ddH2O. Adjust pH 
to 7.6 with HCl. Make up the final volume to 1 liter. 
 




30.3 g Trizma base and 144 g glycine in 1 liter ddH2O. 
For 1X Transfer buffer: combine 100 ml 10X Transfer 





4 g PFA in 100 ml of PBS and heat at 60
o
C with a stir bar 
in a chemical hood until the solution became clear. 
 
4X Separating Buffer 46.75 g of Tris Base in 100 ml ddH2O, adjust pH slowly 
to 8.8 with concentrated HCl, add 1 g SDS and dissolve 
thoroughly. Make up the final volume to 250 ml with 
ddH2O. 
 
4X Stacking Buffer 15.13 g of Tris Base in 100 ml ddH2O, adjust pH slowly 
to 6.8 with concentrated HCl, add 0.25 g SDS and 
dissolve thoroughly. Make up the final volume to 250ml 
with ddH2O. 
 
50X TAE buffer 242 g Tris base, 57.1 ml glacial acetic acid and make up 
the final volume to 1 liter using ddH2O. 
 
5X Electrode Running Buffer 15 g Trizma base, 72 g glycine and 5 g SDS in 1 liter 


















Modified HBSS buffer 
 
 
Protein lysis buffer 
5 % non fat milk powder in 1X PBS/ 0.1% Tween 20,  
at 4°C. 
 
2 mg/ml Glucose , 2.5 mg/ml Taurine , 1% BSA , 1.4 
mmol/l MgCl2 and 0.4 mg/ml collagenase A in HBSS. 
 
1X PBS with 0.1% dextrose containing 5 mg/ml 
collagenase type II and 60 U/ml deoxyribonuclease 
DNAse II. 
 
5 ml FBS, 2 ml DMSO and18 ml DMEM filtered through 
a 0.22 µm strainer and stored at 4°C. 
 
2 mg/ml Glucose, 2.5 mg/ml taurine, 1% BSA, 1.4 
mmol/l MgCl2 in HBSS buffer. 
 
1% Triton-X 100, 150 mM NaCl, 50 mM TRIS, 5 mM 
EDTA, pH 7.5, containing fresh protease (4 mg/ml 
aprotinin, 4 µg/ml leupeptin, 4 µg/ml pepstatin A, 1 mM 
PMSF) and phosphatase (20 mM NaF, 1 mM Na3VO4, 1 
mM Na4O7P2) inhibitors. 
 







Tail lysis buffer 
Citric acid monohydrate, C6H8O7 • H2O, M. wt. 210.14; 
0.1 M solution contains 21.01 g/l. Trisodium citrate 
dihydrate, C6H5O7Na3 • 2H2O, M. wt. 294.12; 0.1M-
solution contains 29.41 g/l. Mix 11.5 ml 0.1M citric acid 
and 88.5 ml 0.1 M trisodium citrate to make sodium 
citrate buffer pH 6.0. 
 
200 mM NaCl, 50 mM Tris/Cl pH.8, 10 mM EDTA pH. 









Supplier Cat. Number 
0.05% Trypsin EDTA (1X) Gibco® 25300-054 
96-well, round bottom suspension cells SARSTEDT AG &Co. 831.837.500 
Cell Scraper 25 cm, SARSTEDT AG &Co. Ref 83.1830 
Dimethyl sulfoxide (DMSO) Sigma D-5879 
DMEM Invitrogen 11960 
DPBS (1X) -CaCl2, -MgCl2 Gibco® 14190-094 
Endothelial Cell Basal Medium MV Kit PromoCell C-22120 
Fetal Bovine Serum (FBS) Gibco® 10270-106 
Gelatin Fluka / Sigma 48720 
HBSS (1X) -CaCl2, -MgCl2 Gibco® 14170-112 
Medium199 10X Sigma M0650 
NUNC multidishes 24-well plate NUNC, Thermo Fisher 
Scientific Inc. 
142475 
NUNC multidishes 6-well plate NUNC, Thermo Fisher 
Scientific Inc. 
140685 
NUNC multidishes 96-well plate NUNC, Thermo Fisher 
Scientific Inc. 
167008 
NUNC tissue culture dish 100 x 15 mm NUNC, Thermo Fisher 
Scientific Inc. 
150679 
NUNC tissue culture dish 60 x 15 mm NUNC, Thermo Fisher 
Scientific Inc. 
150288 
Nutlin-3a Sigma SML0580 
Penicillin/Streptomycin (P/S) Sigma P4333 
Pifithrin-α Sigma P4359 
Rat tail collagen type 1 BD Bioscienses 354236 
Recombinant Human TGF-beta 1 R& D systems 240-B-002  
Serological pipette 10ml SARSTEDT AG &Co. 861.254.001 
Serological pipette 25ml SARSTEDT AG &Co. 861.685.001 
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Serological pipette 2ml SARSTEDT AG &Co. 861.252.001 
Serological pipette 50ml SARSTEDT AG &Co. 861.689.001 
Serological pipette 5ml SARSTEDT AG &Co. 861.253.001 




2.6.1. Primary antibodies 
 
Antigen Antibody type Supplier Cat. Number 
    
ACTIVE® Caspase-3 Rabbit polyclonal Promega G7481 
    
CA IX (H-120) Rabbit polyclonal Santa Cruz SC-25599 
    
Carbonate dehydratase IX Rabbit polyclonal Bioss bs-4029R 
    
CD45 (30-F11) Rat monoclonal Santa Cruz SC-53665 
    
Cleaved Caspase-3  
(Asp175)(5A1E) 
Rabbit monoclonal Cell Signaling 9664 
    
Collagen Type I Rabbit polyclonal Milliore AB765P 
    
FSP-1 Rabbit polyclonal Dako A5114 
    
HIF1α Rabbit polyclonal abcam ab2185 
    
MDM2 Mouse monoclonal BD 
Pharmingen™ 
556353 
    
MDM2 (C-18) Rabbit polyclonal Santa Cruz SC-812 
    
p21 Mouse monoclonal BD 
Pharmingen™ 
556430 
    
39 
 
p53 (1C12) Mouse monoclonal Cell Signaling 2524 
    
p53 (FL-393) Rabbit polyclonal Santa Cruz SC-6243 
    
PECAM-1 (MEC 13.3) Rat monoclonal Santa Cruz SC-18916 
    



















Supplier Cat. Number 
Alexa Fluor 488 goat anti-rabbit IgG 
(H+L)  
 
Mo Bi Tec A11070 






ECL™ Anti-mouse IgG, HRP linked 
whole antibody( from sheep) 
 
GE Healthcare NA931V 
 
 
ECL™ Anti-rabbit IgG, HRP linked 
whole antibody (from donkey) 
 
GE Healthcare NA934V 












MFP488 goat anti-rat IgG (H+L) 
 
Mo Bi Tec MFP-A1006 
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MFP555 goat anti-mouse IgG (H+L) 
 
Mo Bi Tec MFP-A2422 
MFP555 goat anti-rabbit IgG (H+L) Mo Bi Tec MFP-A2428 
 
2.7. Software  
 
Product Version Company 
   
AxioVision Version 4.8.2 Carl Zeiss 
 
AlphaEase FC™ Version 4.1.0 Alpha Innotech 
 
BD FACS DIVA Version 6.1.3 BD Biosciences 
 
C-View Version 2.1.010703 Digital Video Camera Company 
 
GraphPad Prism Version 5 GraphPad Software 
 
Image-Pro Plus Version 4.5.0.29 Media Cybernetics  
  
iQ5 Software Version 170-9753 BIO-RAD 
 




















2.8. Cell Culture Experiments 
 
2.8.1. Endothelial Cell Lines 
 
2.8.1.1. Human Cardiac Microvascular Endothelial Cells  
 
Primary Human Cardiac Microvascular Endothelial Cells (HCMEC) were purchased from 
Promocell (Catalog number C-12285). HCMEC are isolated from heart ventricles from a 
single donor. These cells stain positive for CD31 and Willebrand factor and negative for 
smooth muscle alpha-actin. HCMEC closely interact with cardiomyocytes and therefore have 
a distinctive phenotype from other microvascular endothelial cells. HCMEC play an 
important role in the physiological regulation of coronary blood flow and capillary exchange.  
 
2.8.1.2. Human Umbilical Vein Endothelial Cells  
 
Primary Human Umbilical Vein Endothelial Cells (HUVEC) were also purchased from 
Promocell (Catalog number C-12200). HUVEC are isolated from the vein of the umbilical 
cord and are commonly used for physiological and pharmacological investigations, such as 
macromolecule transport, blood coagulation, angiogenesis, and fibrinolysis. 
 
 
(Figure adopted from ScienCell Research Laboratory.) 
 
Figure 2.1. Microscopic image of HCMEC and HUVEC. HCMECs isolated from human heart and HUVECs 





2.8.2. Cardiac Endothelial Cell Isolation  
 
Coronary microvascular endothelial cells (CMECs) were isolated according to the methods 
published previously  pr.
115
 Hearts were removed from 4 mice after cervical dislocation under 
2% isoflurane anaesthesia and placed into ice-cold PBS. Fresh harvested hearts were 
immediately dipped into 70% ethanol to devitalize membranes and back to cold PBS. Fat, 
connective, vascular and valve/atrial tissue were removed from the hearts followed by cutting 
the hearts open to wash away the blood. The hearts were chopped into small pieces (1-2 
mm
3
) in 25 ml modified HBSS buffer and spun at 500rpm for 1 min. The pellet of the 
fragments was digested in 5 ml collagenase buffer for 5 min at 37°C with shaking every 1 
min. The collagenase digestion was repeated 4 times with supernatant taken out after each 
digestion. Trypsin digestion was subsequently applied on the remaining pellet with 5 ml 
trypsin buffer for 5 min at 37°C with shaking every 1 min and repeated 4 times. In this case, 
heart segments were digested with collagenase to remove myocytes and fibroblasts and 
subsequently with trypsin to free endothelial cells and smooth muscle cells. After each trypsin 
digestion, the supernant (~5 ml) was taken into a tube containing 1 ml FCS and combined at 
the end of the digestion, to which another 15 ml CMEC medium was added and centrifuged 
at 1200 rpm for 5 min. The pellet was resuspended in CMEC medium and seeded into 1% 
gelatin coated T75 flask. After incubating for 2 hours and 24 hours at 37°C with 5% CO2, the 
medium and non-adherent cells (fibroblasts and blood cells) were removed and replaced with 
fresh CMEC medium. CMECs were cultured in CMEC medium (FCS 10%, 
Penicillin/Streptomycin 100 g/ml, L-Glutamine 2 mmol/l, Endothelial cell growth 
supplement 10 g/ml, heparin 5 g/ml, hydrocortisone 1 g/ml, 2-mercaptoethanol 1µmol/L, 
mEGF 10 ng/ml, ascorbic acid 1 g/ml, VEGF 0.5 ng/ml, IGF-1 10 ng/ml in 1000 mg/L 
glucose DMEM) and medium was changed every two days. CMECs were used for 
experiment at passage 1-2. 
 
To isolate cardiac CD31-positive and -negative cells, cells were subsequently surface labeled 







2.8.3. Generation of Stable p53 Knockdown Cell Line 
 
Deletion of p53 from endothelial cells were done in collaboration with
 
Xingbo Xu and 
Xiaopeng Liu, members of Prof. Dr. med. Elisabeth Zeisberg lab. We have used lentivirus 
based Human p53 shRNA expression vectors or scrambled non-effective shRNA cassette (in 
pGFP-C-shLenti plasmid) obtained from Amsbio to generate a stable p53 knockdown 
endothelial cell line. Lentivirus packaging was performed as previously described 
(Streckfuss-Bömeke et al., 2013)
116
. Briefly, Human Embryonic Kidney 293T (HEK293T) 
cells were plated at 4 × 10
6
 cells per 100 mm dish and incubated overnight. Cells were 
transfected with 10 μg of pLenti-shp53 along with 2.5 μg of Virus packaging plasmid mix by 
using Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. Virus 
collection was performed two times at 48 hours and 72 hours after transfection, the 
supernatant of transfectant was collected and filtered through a 0.22 μm pore-size cellulose 
acetate filter (Millipore). Human Cardiac Microvascular Endothelial Cells (PromoCell) were 
seeded at 2×10
5
 cells per 100 mm dish 1 day before transduction. The medium was replaced 
with virus-containing supernatant supplemented with 5 μg/ml polybrene (Sigma), and 
incubated for 12 hours. 
 
2.8.4. Modulation of p53 and Induction of EndMT in vitro  
 
HCMECs were cultured at 37°C in humidified air with 5% CO2 on gelatine-coated 100 mm 
culture dishes in endothelial cell basal medium supplemented with 2% FCS, 5 ng/ml 
epidermal growth factor, 22.5 µg/ml heparin and 1 µg/ml hydrocortisone. Medium was 
changed every 2 days. After the culture reached 80% of confluent density, the cells were 
subcultured with a ratio of 1:4. For EndMT induction, HCMECs were serum-starved and 
incubated with 10 ng/ml TGFβ1 for 6 or 12 days, with nutlin-3a and pifithrin- being 









2.8.5. Endothelial Cell Functionality Assays 
 
2.8.5.1. In vitro 3-D Spheroid Angiogenesis Assay 
 
The 3-dimensional spheroid angiogenesis assay was established by Thomas Korff 
117
. It is a 
functional assay to test whether cells can form a vascular structure. This assay consists of  
two main steps: 
 
2.8.5.1.1. Generation of Spheroids 
 
To generate spheroids, HCMVCs were detached and resuspended in Endothelial cell growth 
medium containing 20% methyl cellulose solution. The stock solution of methyl cellulose 
was prepared by dissolving  7 g of methyl cellulose (pre autoclaved) in preheated 500 ml of 
M199 medium (60°C). The solution was mixed for 30 minutes using a magnetic stirrer, and 
stored at 4°C overnight. Penicillin/Streptomycin (P/S) was added to the methyl cellulose 
stock solution and  stored in 50 ml aliquots . The solution was spun down at 4°C for 2 hours 
at 4000 rpm to remove the precipitate or undissolved methyl cellulose. The clear gel-like 
supernatant after centrifugation, was used for experiments. Cells were counted and adjusted 
to a concentration of 4x10
4 
cells in 10 ml (for one 96-well plate) of growth medium 
containing 20% methyl cellulose solution. Cells suspension (100 µl/well) was  seeded in non-
adherent round-bottom 96-well plates using a 12-channel pipette  and incubated at 37°C. 
After 24 hrs of incubation, cells formed a single spheroid.  
 
2.8.5.1.2. Culture in Collagen Type I 
 
After 24 hours of incubation, spheroids were harvested using 1000 µl pipette tip and 
embedded into collagen gels. A pre- warmed humidified 24-well culture plates were prepared 
in advance in 37°C incubator.   
 
Before harvesting the spheroids, methylcellulose stock solution with 20% FBS and type I rat 
tail collagen diluted 1:1 with filtered 0.1% acetic acid and mixed with 10X M199 medium 
and neutralized filtered 0.2 N NaOH immediately before use. Spheroids were harvested 
carefully without disturbing the spheroid structures. After centrifugation at 1200 rpm for 3 
minutes, spheroid pellets were overlaid with methylcellulose stock solution and gently diluted 
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equal amount with neutralized collagen working solution. The mixed spheroid containing gel 
was quickly transferred in duplicates into pre-warmed 24-well plates by adding 1 ml 
(containing approximately 40 spheroids) to each well and incubated at 37°C for 30 minutes. 
100 µl of culture medium were added to each well after solidification of the collagen, and 
incubated in a 37°C incubator for at least 24 hours. The total sprout length and no. of sprouts 
of 15-20 randomly selected spheroids was measured to calculate mean sprout length and 
mean no. of sprouts for each group. Pictures were taken using AxioVision software and data 
were evaluated by Image-Pro Plus. Total sprout length means the length of all sprouts grown 
out of an individual spheroid. 
 
2.8.6. Freezing and Thawing of Cells 
 
Cells to be preserved were detached by T/E solution at RT until all the cells had detached 
from the surface of the dishes. Trypsin was neutralized by the addition of cell type-dependent 
culture medium. Cells were spun down at 1200 rpm for 5 min, the supernatant was discarded 
and the cell pellets were resuspended in freezing medium. The cell suspension was gently 
mixed and transferred into polypropylene cryovials (1 ml per vial). The vials were transferred 
to a freezing container and kept at -80°C at least overnight before being transferred to liquid 
nitrogen storage tanks for long-term storage. 
 
For thawing the frozen cells, cells in cryovials were thawed at 37
o
C in a water bath for 
approximately 90 seconds and transferred to a 15 ml centrifuge tube containing 10 ml of pre-
warmed (37°C) growth medium. Cells were centrifuged at 1500 rpm for 5 minutes and the 
supernatant was discarded to remove the freezing medium. Cell pellets were again 
resuspended gently with pre-warmed growth medium and then transferred to new culture 
dishes coated with 0.1% gelatin. Cell cultures were incubated at 37
o
C in humidified air with 









2.9. Experiments in Mice 
 
2.9.1. Experimental Animals 
 
To generate mice with inducible endothelial cell-specific p53 deletion (End.p53-KO), mice 
with loxP-flanked (floxed, fl) p53 alleles (courtesy of Arnold Berns; C57BL/6 background)
118
 
were mated with mice expressing a Cre recombinase-estrogen receptor fusion protein ER(T2) 
under control of the endothelial receptor tyrosine kinase (Tie2) promoter (courtesy of Berndt 
Arnold; C57BL/6 background).
119
 This inducible Tie2.Cre mouse line has been previously 
shown to allow efficient temporal gene deletion exclusively in endothelial cells, including the 
heart, whereas the percentage of recombined cells was found to be negligible in 
hematopoeitic cells.
119
 Cre recombinase activity was induced by feeding 5 to 6 week-old 
mice with rodent chow containing 400 mg/kg tamoxifen citrate (TD55125; Harlan Teklad) 
for 6 weeks.
119,118;120
 Successful p53 gene excision was confirmed by PCR analysis of 
genomic DNA from tail biopsies.
118, 119
 Cre-wildtype (WT) x p53fl/fl mice fed tamoxifen chow 
and Cre-tg x p53fl/fl mice on normal rodent chow were used as controls (End.p53-WT). Age- 
and gender-matched littermates were used throughout the study. All animal care and 
experimental procedures had been approved by the institutional Animal Research Committee 
and complied with national guidelines for the care and use of laboratory animals.  
 
2.9.2. Transverse Aortic Constriction 
 
Female mice were anesthetized via 2% isoflurane inhalation and subjected to minimally 
invasive TAC surgery over a 26-gauge needle.
121
 Anesthesia depth was monitored by 
observing the respiratory rate and the toe-pinch reflex test. Sham-operated mice, in which the 
aortic arch was exposed, but not ligated, were also examined. Three days after surgery, the 
pressure gradient over the aortic ligature was determined using pulsed wave Doppler. 
Echocardiography was performed before and at tissue harvest 8 and 20 weeks after TAC. At 
tissue harvest, hearts were rapidly excised and weighed. Next, the atria were removed and the 
ventricles immediately divided into two parts. The top half of each heart was placed in saline 
at 4
o
C for cryoprotection, subsequently embedded in tissue freezing medium and processed 
for histological analysis. The bottom half of each heart was stored at -80°C and subsequently 





Before TAC            After TAC  
                             (figure, kind courtesy of PD Dr. med. Karl Toischer) 
 
Figure 2.2. Transverse Aortic Constriction. Representative cartoon showing the increase in left ventricle size 
in response to increased afterload. 
 
2.9.3. Doxorubicin Injection  
 
End.p53-WT and End.p53-KO male mice aged 11-15 weeks were injected intraperitoneally 
(i.p.) with a single dose of either doxorubicin hydrochloride (Sigma; 20 mg/kg BW in 150 µL 
saline) or saline. Echocardiography was performed before and at tissue harvest 5 days or 8 
weeks. Mice were sacrificed by cervical dislocation after 5 days or 8 weeks post Dox 
injection and heart tissues were subsequently collected, weighed and divided into two parts. 
The top half of each heart was placed in saline at 4°C for cryoprotection, subsequently 
embedded in tissue freezing medium and processed for histological analysis. The bottom half 
of each heart was stored at -80°C. Each treatment group consisted of five to seven mice.  
 
2.9.4. Transthoracic Echocardiography 
 
Two-dimensional (2D) directed echocardiography was performed by a blinded examiner 
before and the indicated time points after surgery in mice under 1.5% isoflurane anesthesia 
using the Vevo 2100 system (Visualsonics) equipped with a 30 MHz center frequency 
ultrasound transducer.
121
 Typically, heart rates were 460±15 beats/minute, respiratory rates 
were 125±3.8 breaths/minute. Original M-mode recordings were used to determine the end-
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diastolic (EDD) and end-systolic (ESD) LV chamber diameter and posterior wall thickness 
(PWTh). Echocardiographic LV mass (LVM) was estimated using the formula: 1.055 x 
([AWTh + EDD + PWTh]³ - EDD³). LV fractional shortening (FS) was calculated as (EDD -
 ESD) / EDD x 100. 
 
2.9.5. Unilaterial Hindlimb Ischemia  
 
Ten to twelve week-old male End.p53-WT and End.p53-KO mice were used to examine the 
neovascularization in vivo using the unilateral hindlimb ischemia mouse model.
122;123 
End.p53-WT mice without tamoxifen food were also examined simultaneously to analyze the 
effect of tamoxifen in reperfusion after hindlimb ischemia. After anesthesia by intraperitoneal 
injection of xylazine / ketamine hydrochloride, unilateral hindlimb ischemia was induced by 
permanent ligation of the right femoral artery (immediately distal to the origin of the deep 
femoral artery) as well as the distal portion of the saphenous artery with 6-0 silk sutures. 
Perfusion was determined before and immediately after ischemia induction as well as on day 
7, 14, 21 and 28 after surgery using laser Doppler perfusion imaging. Perfusion in the 
contralateral hindlimb was used as internal control (set at 100%).  
 
 
(Figure adapted from Limbourg A et al. Nat Protoc 2009;4:1737-46) 
Figure 2.3. Unilaterial Hindlimb 
Ischemia: Ventral aspect of right mouse 
thigh and upper hind limb after hair 
removal (a). Surgical skin incision (5 
mm) beginning from the groin skinfold 
following and immediately lateral to the 
vascular contours visible through the 
skin (b). Blunt dissection and separation 
of the femoral artery and vein (c). 
Insertion of a surgical thread underneath 
the femoral artery (d). Faint appearance 
of collaterals from the deep branch 
(arrowhead). Ligation of the femoral 
artery distal to the origin of the deep 
branch by a triple surgical knot (e). 
Blood flow is diverted to collaterals 
(dashed white arrow) and collateral 
arteries now appear prominent (compare 
arrowheads from d and e). Over-and-





Histochemical analyses were performed on 5 µm-thick frozen, acetone-fixed cross sections 
through the LV of mice 8 and 20 weeks after TAC, or through the lower hindlimb of mice 4 
weeks after femoral artery ligation. Cardiac fibrosis was determined by Masson’s trichrome 
(MTC) staining. Interstitial collagen was visualized using picrosirius red staining. Capillary 
endothelial cells were assessed after incubation with monoclonal antibodies against CD31 
followed by Cy3-labeled secondary antibodies. Cell nuclei were visualized using 4',6-
diamidino-2-phenylindole (DAPI). In some mice, the functionality of cardiac vessels was 
assessed by intracardiac (i.c.) injection of endothelial fluorescein (FITC)-conjugated 
Griffonia simplicifolia isolectin B4 (GSL-I; 50 µg in 200 µl saline) 15 min prior to sacrifice 
with an overdose of isoflurane. Cells not positive following CD31 antibody incubation or 
endothelial cell-lectin perfusion are denoted as ‘CD31-negative cells’ or ‘lectin-negative 
cells’, respectively. Cardiomyocyte membranes were visualized using FITC-labeled wheat 
germ agglutinin (WGA) followed by determination of the minimal single cardiomyocyte 
cross-sectional area (CSA). Per cross section, at least 10 randomly selected cardiomyocytes 
were evaluated and results averaged. Cardiac apoptosis was examined using Terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) or antibodies against 
activated caspase-3 and p53. A rabbit anti-carbonic anhydrase IX (CAIX) antibody was used 
as surrogate marker for hypoxia.
124
 Fibroblast-specific protein (FSP)-1 was detected using a 
polyclonal rabbit anti-mouse antibody. All morphometric analyses were performed using 
image analysis software.  
 
4. Molecular Biology Methods 
 
4.1. Genomic DNA Isolation from Mouse Tail  
 
Mouse tail biopsies were used to isolate genomic DNA. Tail biopsies were lysed using tail 
lysis buffer. Tail biopsies with tail lysis buffer (600 µl) was incubated at 56
o
C overnight with 
shaking (600 rpm). 200 µl of saturated NaCl (2M) was added to lysate and centrifuged at 15 
krpm (max. speed) for 30 min at 4
o
C. Then, 750 µl of supernatant were transferred to a fresh 
1.5 ml tube and 450 µl of cold isopropanol added, mixed gently and centrifuged at 15krpm 
for 30 min at 4
o
C. Supernatant was discarded and pellet was washed with 500 µl of 70% 
50 
 
EtOH and centrifuged 10 krpm for 15 min at 4
o
C. Finally,the gDNA pellet was air dried at 
RT and resuspended in 20-30 µl of nuclease free water.  
 
Genomic DNA from the mouse tails were used for genotyping. The mouse carrying the p53 
flox alles were identified by PCR using the following primers: primer A: p53-int1-fwd:5'-
CACAAAAACAGGTTAAACCCAG, primer B: p53-int1-rev: 5'-AGCACATAGGAGGCA 
GAGAC, primer C: p53-int 10-fwd: 5'-AAGGGGTATGAGGGACAAGG; primer D: 5'-GA 
AGACAGAAAAGGGGAGGG and for Cre the primers are Cre1 5' CGAGTGATGAGGTT 
CGCAAG and Cre2 5' TGAGTGAACGAACCTGGTCG. The PCR condition for p53 flox 
alleles and cre is 95
o
C for 2 min, 95
o
C for 30 sec, 58
o
C for 30 sec, 72
o
C for 1 min, reapeat for 
45 cycles, 72
o
C for 10 min and soak at 4
o
C. The PCR product size of p53 intron 1, intron 10 
and cre are 288 bp, 431 bp and no band for wild type mice and 370 bp, 584 bp and 390 bp for 
p53 flox/ flox + cre heterozygous mice respectively. 
 
4.2. Isolation of Total RNA from Heart Tissue 
 
RNA was extracted using the TRI Reagent® Solution (Ambion) according to the 
manufacturer's instructions. The tissue samples were homogenized in 10–20 volumes of TRI 
Reagent® solution. The homogenate was incubated for 10 min at RT. Then, 100 μl of 
chloroform per 1 ml of TRI Reagent solution was added, mixed well and incubated at room 
temp for 10min. Then, the homogenate was spun down at 12,000 x g for 15 min at 4°C, and 
the aqueous phase was transferred to a fresh tube. 500 µl of isopropanol per 1 ml of TRI 
Reagent solution was added to aqueous sample to precipitate the nucleic acids. The sample 
was incubated at RT for 10 min. Then, the sample was centrifuged at 12,000 x g for 8 min at 
4°C. The supernatant was removed without disturbing the pellet. 1 ml of 75% ethanol per 1 
ml of TRI Reagent solution was added to each sample to wash the RNA pellets and then 
centrifuged at 7,500 x g for 5 min at 4°C. The ethanol was removed without disturbing the 
pellet. Residual ethanol was removed by centrifuging again briefly and removing the 
remaining ethanol with a fine tip pipette. RNA pellet was air dried for 3–5 min and 






4.3. Determination of RNA Quality and Concentration 
 
The quality and concentration of RNA was determined by NanoDrop® ND 1000. The ratio 
of absorbance at 260 nm and 280 nm is used to assess the purity of RNA. A ratio of ~ 2.0 is 
generally accepted pure for RNA. If the ratio is lower, it may indicate the presence of protein, 
phenol or other contaminants that absorb strongly at or near 280 nm. The resultant 260:280 
ratio for the nucleic acid being studied will be approximately equal to the weighted average 
of the 260/280 ratios for the four nucleotides present. For nucleic acid quantification, a 
modification of the Beer-Lambert equation is used to calculate sample concentration (C=(A 
*ε)/b), where C is nucleic acid concentration in ng/µl, A is absorbance in AU, ε is the 
wavelength dependent extinction coefficient in ng-cm/µl and b is the pathlength in cm.  
 
4.4. Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 
RT or cDNA synthesis was performed using the M-MLV Reverse Transcriptase. A total of 1 
µg total RNA was used for each RT reaction together with random hexamer primers, 
RiboSafe RNase Inhibitor, MgCl2 and dNTPs. The final volume of RT reaction was 20 μl. In 




Total RNA 1µg x μl 
M-MLV RT 5X buffer 4 μl 
dNTPs 2 μl 
MgCl2 4 μl 
RNase Inhibitor 40 U/µl 0.6 μl 
Random primers 0.2 μl 
Reverse Transcriptase, 200 U 0.4 μl 
DEPC water 
Final volume 






The mixtures of 20 µl final volumes was mixed by gentle pipetting and then spun down. The 
contents were incubated at 42°C for 20 min. RT reaction was inactivated by heating to 99°C 
for 5 min. The cDNA was stored at -20°C or directly used as a template for PCR 
amplification. 
 
PCR was performed to standardize the primers to optimize amplification condition with 
GoTaq Polymerase using 2 µl of cDNA per reaction. Amplification reactions were performed 
in an automatic thermocycler equipped with a heatable lid. The following reagents were 
prepared and added to 0.2 ml microcentrifuge tubes on ice: 
 
 
cDNA   2 µl 
DEPC water 13 µl 
5X GoTaq buffer   5 µl 
MgCl2, 25 mM 1.8 µl 
Sense primer, 5 µM 1.5 µl 
Antisense primer, 5 µM 1.5 µl 
GoTaq DNA polymerase, 50 U/µl 0.2 µl 
Final volume 25 µl 
 
Mixtures were gently mixed and spun down prior to reaction. Primer sequences, annealing 
and extension conditions are shown in section 4.7 and had been carefully established 
previously. Of note, the number of PCR cycles for each set of primers was verified to be in 
the linear range of the amplification. The initialization step is heating the reaction to a 
temperature of 95°C for 1-3 min to ensure the template DNA is completely denatured. The 
final elongation step is performed at a temperature of 72°C for 10 min after the last PCR 
cycle to ensure the remaining single-stranded DNA is fully extended. A standard PCR 








Initial denaturation 95°C for 3 min, 1 cycle 
followed by 30-40 cycles of; 
Denaturation 94°C for 30 sec 
Annealing For the temperature, refer to (section 4.7), 
30 sec 
Extension 72°C, time depends on the size of PCR 
product, 1 kb/min 
Final extension 72°C for 10 min, 1 cycle 
Soak 4°C  
 
Products were stored at 4°C until analysis. 20 µl of PCR products were analyzed on 1.5 or 
2% agarose gels and visualized by ethidium bromide.  
 
4.5. Quantitative real-time PCR 
 
Real-time PCR (qRT-PCR) was used to amplify cDNA products to study and compare gene 
expression between groups. SYBR
®
 Green PCR Master Mix was used to detect and quantify 
PCR products in real-time reactions
125
. SYBR Green is a fluorescent intercalating dye which 
binds to double-stranded DNA and upon excitation emits light.
126
 Thus, as a PCR product 
accumulates, fluorescence increases. Real-time PCR record fluorescence and report the 
results as a Ct (cycle threshold). The Ct is defined as the number of cycles required for the 
fluorescent signal to cross the threshold. This threshold is a fluorescence value slightly above 
the background fluorescence measured before exponential growth starts. 
 
Total RNA was isolated using TRI Reagent® solution, and the amount and quality checked 
by Nanodrop. One µg RNA was reversed transcribed into cDNA, followed by quantitative 
PCR using real-time assessment of SYBR
®
 Green and the iCycler iQ Detection system. 
qPCR primers and conditions are listed in section 4.7. Starting quantities were extrapolated 







The following reagents were prepared and added to a 96 well-plate on ice: 
 
 
qPCR reaction  
2X SYBR Green PCR Master Mix   10 µl 
cDNA   2 µl 
DEPC water   5 µl 
Sense primer, 5 µM 1.5 µl 
Antisense primer, 5 µM 1.5 µl 
Final volume  20 µl 
 
Duplicate aliquots (each 20 µl) were carefully added into the appropriate wells and the plate 
was sealed with adhesive film. After a brief centrifuge spin to distribute the mixtures to the 
bottoms of the wells, qPCR reaction was performed using default conditions, with exception 
of the melting temperature and the number of cycles which were altered according to the 
primer set used in the particular reaction: 
 
Initial denaturation 50°C for 2 min followed by 95°C for 
10 min, 1 cycle 
Annealing and extension 95°C for 15 sec ; 60°C for 1 min, 35-40 cycles 
Disassociation/melting curve 15 sec each at 95, 60, and 95°C 
Soak 4°C  
 
The specificity of the SYBR Green assay was verified by melting curve analyses and the 
results were analyzed by comparative Ct method 
127
, with: 
          [delta][delta]Ct = [delta]Ct,sample - [delta]Ct,reference 
            Fold change = 2
[delta][delta]Ct 
 
All qPCR data (two or more biological replicates with three technical replicates each) were 
calculated using the delta delta Ct method and normalized to glyceraldehyde-3-phosphate 






4.6. Agarose Gel Electrophoresis Detection of PCR Amplicons 
 
1.5 or 2% agarose gels were prepared depending upon the size of DNA fragment. For this 
purpose, the required amount of agarose was measured and 1X TAE buffer was added. 
Agarose was dissolved by boiling in a microwave oven until the solution appeared clear. 
Agarose solution was allowed to cool down till 60°C and ethidium bromide was added to a 
concentration of 0.5 µg/ml. The gels were cast in the casting chamber and were allowed to 
polymerize at RT. 20 µl of PCR products and DNA ladder were loaded in the wells. 
Electrophoresis was performed at 80-100 volts and DNA was visualized in the gel by 
addition of ethidium bromide and placed on an UV transilluminator. Ethidium bromide binds 
to both single-
 
and double-stranded nucleic acids (DNA and RNA) by intercalating between 
the bases
128
 and is fluorescent, meaning that it absorbs invisible UV light and transmits the 




4.7. Primer Sequences and qRT-PCR Conditions 
 
Gene Primer sequence (in 5‘ – 3‘ direction) Tm(°C) cycles ref 
  

























































Slug F: CGCTCCTTCCTGGTCAAGA 60 40 * 
R:AGGTATAGGGTAACTTTCATAGAGATA 
 





Snail F: GTGCCCACCTCCAAACCC 60 40 * 
R: AAGGACATGCGGGAGAAGG 
 





Twist F: TGATAGAAGTCTGAACACTCGTTTG 60 40 * 
R: GGCTGATTGGCAAGACCTCT 
 




















4.8. Western Blot Analysis 
 
Frozen heart tissue was pulverized on liquid nitrogen and resuspended in protein lysis 
buffer.
122
 After incubation for 20 minutes on ice, heart lysates were cleared by centrifugation 
at 13,000 rpm for 10 minutes at 4ºC. Equal amounts of protein (40 µg) were boiled for 5 min 
in 2X loading buffer and fractionated by SDS polyacrylamide gel electrophoresis together 
with molecular weight standards and transferred to nitrocellulose membranes. Membranes 
were blocked in 5% bovine serum albumin/ 5% milk powder for 1-2 hours prior to incubation 
with primary antibodies overnight at 4ºC with antibodies against p53, p21 or murine double 
minute (mdm)-2, Hif1α, Vegf or Gapdh. Protein bands were visualized using horseradish 
peroxidase-conjugated secondary antibodies (dilution, 1:3,000) for 2 hours, followed by 
detection with SuperSignal
®
 West Pico Substrate. Protein bands were quantified by 




4.9. Statistical Analysis 
 
Quantitative data are presented as mean ± standard error of the mean (SEM). Differences 
were tested by Student’s t test for unpaired means or paired means, if findings in the same 
animal before and after an intervention were compared. If more than two groups were 
compared, the One Way Analysis of Variance (ANOVA) test was performed, followed by 
Bonferroni’s Multiple Comparison test. Frequencies were compared using the χ
2
 test. 
Statistical significance was assumed if P reached a value <0.05. All analyses were performed 






5.1. Generation of Endothelial-Specific p53 Knockout Mice 
 
To generate endothelial-specific p53 knockout mice (End.p53-KO), mice carrying floxed p53 
alleles
21
 were crossed with mice expressing Cre recombinase under control of an inducible 
Tie2 promoter (Tie2.ERT.Cre).
119
 Gene deletion was achieved by feeding mice with 
tamoxifen-containing chow and confirmed by PCR analysis of genomic DNA from tail 
biopsies (Figure 5.1.A). Quantitative real time PCR analysis revealed that p53 mRNA levels 
were significantly reduced (to approximately 10%) in CD31-positive cells isolated from 
hearts of End.p53-KO mice compared to CD31-positive cells isolated from End.p53-WT 
mice or CD31-negative cells (Figure 5.1.B).  
 
A        B 
 
 
Figure 5.1. Genotyping of endothelial p53 knockout and wildtype mice. A, Genomic DNA was isolated 
from mouse tail biopsies obtained before and 6 weeks after feeding mice with tamoxifen citrate-containing chow 
and amplified by PCR. Floxed p53 alleles were identified using forward (F) and reverse (R) primer against 
intron 1 or intron 10. Excision of p53 exons was confirmed in Cre recombinase transgenic mice. MW, molecular 
weight marker. B, qPCR analysis of p53 mRNA expression in CD31-positive and CD31-negative cells, isolated 
from hearts of End.p53-WT (grey bars) and End.p53-KO (white bars) mice. ***P<0.001 vs. CD31-positive cells 
isolated from End.p53-WT mice. Significant differences between CD31-positive and CD31-negative cells from 




Flow cytometry showed 24.5% of Tie 2 expression in cardiac cells, but only 1.4 and 2.7% in 
blood and spleen mononuclear cells, respectively, and no CD45-positive cells were detected 
in the heart (Figure 5.2).  
 
 
Figure 5.2. Flow cytometry of Tie2- and CD45-positive cells isolated from blood, spleen and heart of 
End.p53-WT mice. 
 
Of note, EC-specific p53 deletion per se did not affect survival up to 12 months and was not 
associated with spontaneous tumor formation (not shown). 
 
5.2. Endothelial p53 Deletion Protects Against Cardiac Hypertrophy and 
Dysfunction After Pressure Overload  
 
To induce cardiac hypertrophy and heart failure, female mice were subjected to TAC surgery. 
Mean pressure gradients over the aortic valve were similar in both groups, i.e. 713.8 mmHg 
in End.p53-KO and 743.7 mmHg in End.p53-WT mice (P=0.51) (Figure 5.3.A). As shown 
in Figure 5.3.B, survival (after exclusion of mice that died within the first 24 hours after 
surgery) was significantly improved in End.p53-KO mice (5 out of 34 mice died) compared 
to their End.p53-WT counterparts (16 out of 41 mice died; P=0.020). Mice were not followed 
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Figure 5.3. Effect of endothelial p53 deletion on survival. A, Mean pressure gradients over the aortic valve, 
i.e. 713.8 mmHg in End.p53-KO and 743.7 mmHg in End.p53-WT mice (P=0.51). B, Kaplan-Meier survival 
analysis of sham- (n=19) or TAC-operated End.p53-WT (n=41) and End.p53-KO mice (n=34). 
 
Serial echocardiographic measurements (representative M mode recordings are shown in 
Figure 5.4.A) revealed a significant decline in cardiac function in End.p53-WT mice, 
beginning at week 4 after TAC and progressing towards week 20 compared to End.p53-KO 
mice. Fractional shortening (FS) was significantly reduced in End.p53-WT mice compared to 
End.p53-KO mice at 8 and 20 weeks after TAC (Figure 5.4.B). Compared to baseline, a 
significant increase in the endsystolic (Figure 5.4.C) and enddiastolic (Figure 5.4.D) LV inner 
diameter was observed in both the genotypes, which progressed further only in End.p53-WT 
mice and was significantly more pronounced compared to End.p53-KO mice at 20 weeks 
after TAC. At this time point, both the mean PWTh (P<0.05; Figure 5.4.E) and 
echocardiographically determined LV weight (P<0.05; Figure 5.4.F) were significantly 
increased in End.p53-WT compared to End.p53-KO mice, and this observation was further 
confirmed by determining the actual heart weight at necropsy (Figure 5.5.A) after 8 and 20 








A       B 
 
C       D 
    
E       F 
    
Figure 5.4 Effect of endothelial p53 deletion on cardiac hypertrophy and function. A, Representative M-
mode tracings before (baseline) as well as 8 and 20 weeks after TAC. Mean values for fractional shortening (FS; 
B), endsystolic (ESD; C) and enddiastolic (EDD; D) inner LV diameters, posterior wall thickness (PWTh; E), 
LV weight determined by echocardiography(F) Grey bars: End.p53-WT mice; white bars: End.p53-KO mice; 
dotted bars: sham-operated mice. *P<0.05, **P<0.01 and ***P<0.001 vs. sham, #P<0.05, ##P<0.01 and 
###P<0.001 vs. baseline. Significant differences between End.p53-WT and End.p53-KO mice are indicated 
within the graphs. 
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Cardiac hypertrophy was also determined in the histological level, the mean cardiomyocyte 
cross-sectional area (CSA; Figure 5.5. C and B) was significantly increased after TAC in both 
genotypes, although to a lesser extent in End.p53-KO mice (P<0.05 at 20 weeks after TAC), 
suggesting that inducible deletion of p53 specifically in endothelial cells ameliorates the 
development of cardiac hypertrophy and the deterioration of cardiac function after pressure 
overload. 
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Figure 5.5. Effect of endothelial p53 deletion on cardiac hypertrophy. Heart weight determined at necropsy, 
at baseline and different time points after TAC or sham operation are shown. A and B, results after 
quantification of the cardiomyocyte cross-sectional area (CSA; n=7-16 mice per group) and C, representative 
pictures of WGA-stained myocardial cross sections. Size bars represent 100 µm. Grey bars: End.p53-WT mice; 
white bars: End.p53-KO mice; dotted bars: sham-operated mice. *P<0.05, **P<0.01 and ***P<0.001 vs. sham, 
#P<0.05, ##P<0.01 and ###P<0.001 vs. baseline. Significant differences between End.p53-WT and End.p53-
KO mice are indicated within the graphs. 
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5.3. Endothelial p53 Deletion Reduces Cardiac p53 Accumulation in 
Endothelial and Non-Endothelial Cells after TAC 
 
Cardiac hypertrophy is associated with increased apoptosis and elevated cardiac p53 
levels.
80,81
 Our analyses could confirm these previous findings in End.p53-WT mice, whereas 
cardiac p53 mRNA (Figure 5.6.A) and protein (Figure 5.7.A and D) levels were not altered in 
hearts of End.p53-KO and significantly lower than in End.p53-WT mice, particularly 8 
weeks after TAC. Similar findings were observed for cardiac mRNA and protein expression 
levels of p21 (Figure 5.6.B, 5.7.B and D), a cyclin-dependent kinase inhibitor and 
downstream target of p53. On the other hand, cardiac levels of mdm2, a negative regulator of 
p53-mediated transactivation, were not significantly altered at any of the time points 
examined (Figure 5.6.C, 5.7.C and D).  
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Figure 5.6. mRNA expression of p53 and p53-
regulated factors in banded mouse hearts. The 
relative cardiac mRNA expression levels of p53, 
p21 and mdm2 were analyzed using quantitative 
real time PCR (A-C) Results were normalized to 
Gapdh and expressed as -fold change vs. sham-
operated littermates of the same genotype (set at 
1; dotted bars). *P<0.05, **P<0.01 and 
***P<0.001 vs. sham. Significant differences 
between End.p53-WT and End.p53-KO mice are 
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Figure 5.7. Protein expression of p53 and p53-regulated factors in banded mouse hearts. The relative 
cardiac protein expression levels of p53, p21 and mdm2 were analyzed using Western blot (A-C) in End.p53-
WT (grey bars) and End.p53-KO mice (white bars) (n=8-19 mice per group). Representative Western blot 
findings are shown in D. Results were normalized to Gapdh and expressed as -fold change vs. sham-operated 
littermates of the same genotype (set at 1; dotted bars). *P<0.05, **P<0.01 and ***P<0.001 vs. sham. 
Significant differences between End.p53-WT and End.p53-KO mice are indicated within the graphs.  
 
After the previous result, showing that there is reduction in p53 mRNA and protein levels in 
End.p53-KO mice after TAC, we hypothesized that endothelial p53 deletion might reduce the 
apoptosis in the hearts after TAC in End.p53-KO mice. To test this hypothesis, we first 
stained the heart sections of sham, End.p53-WT and End.p53-KO at 8 and 20 weeks after 
TAC for p53. Interestingly, fluorescence microscopy images (Figure 5.8.A-C) shown not 
only reduced numbers of p53 positive endothelial cells, but also reduced numbers of 
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apoptotic non-endothelial cells in End.p53-KO mice compared to End.p53-WT mice. Sham 














B           C 
        
 
Figure 5.8. Reduced number of p53 positive endothelial and non endothelial cells in End.p53-KO mice. 
Cardiac cross sections were examined for the expression of p53 (A-C). Representative pictures of findings in 
End.p53-WT and End.p53-KO mice after TAC are shown in A. Intravitally isolectin B4 perfused capillaries are 
green, DAPI-positive cell nuclei blue, p53 in red. Size bars represent 100 µm. The summary of findings in n=3-
6 mice per group is shown in B, C . **P<0.01 ***P<0.001 vs. sham. Differences between End.p53-WT and 





5.4. Endothelial p53 Deletion Reduces Apoptosis in Endothelial and Non-
Endothelial Cells After TAC 
 
To assess the effect of endothelial cell p53 deletion in apoptosis after TAC, we stained the 
tissues of sham, End.p53-WT and End.p53-KO after 8 and 20 weeks after TAC with 
apoptotic markers such as cleaved caspase 3 and TUNEL. Fluorescence microscopy 
confirmed not only reduced numbers of lectin-positive (endothelial) cells, but also lectin-
negative (non endothelial) cells, double-immunopositive for activated caspase-3 (Figure 
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Figure 5.9. Effects of endothelial p53 deletion on  caspase-3 levels after TAC. Cardiac cross sections 
through the LV were examined for the expression of activated caspase-3 shown in red, Intravitally isolectin B4 
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perfused capillaries are green, DAPI-positive cell nuclei blue. Representative pictures of findings in End.p53-
WT and End.p53-KO mice after sham or TAC surgery (8 and 20 weeks) are shown in A. Size bars represent 100 
µm. The summary of findings in n=3-6 mice per group is shown in B and C *P<0.05, **P<0.01 and 






B      C 
       
 
Figure 5.10. Effects of endothelial p53 deletion on cardiac apoptosis after TAC. Cardiac cross sections 
through the LV were examined for the expression of terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL)-positive cells are red, Intravitally isolectin B4 perfused capillaries are green, DAPI-positive 
cell nuclei blue. Representative pictures of findings in End.p53-WT and End.p53-KO mice after sham or TAC 
surgery (8 and 20 weeks) are shown in A. Size bars represent 100 µm. The summary of findings in n=3-6 mice 
per group is shown in B and C. *P<0.05, **P<0.01 and ***P<0.001 vs. sham. Significant differences between 
End.p53-WT and End.p53-KO mice are indicated within the graphs. 
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5.5. Deletion of p53 in Endothelial Cells is Associated with Higher Cardiac 
Hif1α and Vegf Expression 
 
Accumulation of p53 in the heart has been shown to be involved in Hif1α degradation, 
angiogenesis inhibition and cardiac dysfunction following pressure overload.
87 
To study the 
importance of endothelial p53 for Hif1α suppression, we examined Hif1 and Vegf protein 
levels in pressure-overloaded hearts of End.p53-WT and End.p53-KO mice. At 8 and 20 
weeks after TAC, i.e. the time points examined throughout this study, Hif1α (Figure 5.11.A 
and B) and Vegf (Figure 5.11A and C) protein expression was found not to be altered in 
End.p53-WT mice, whereas Hif1 and Vegf protein levels were slightly, but significantly 
elevated in End.p53-KO mice at 20 and 8 weeks after surgery, respectively. 
 
                                          A 
 
   B                                        C 
        
Figure 5.11. Role of endothelial p53 for the cardiac and endothelial response to hypoxia at 8 and 20 weeks 
after TAC. A-C, Western blot analysis of cardiac Hif1α and Vegf protein levels in End.p53-WT and End.p53-
KO mice at different time points after transverse aortic constriction (TAC) or sham operation. Representative 
membranes are shown in A (8 and 20 weeks after TAC) Representative findings of the quantitative analysis of 
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n=3 independent experiments for Hif1α and Vegf protein levels in B and C.  *P<0.05 vs. sham. Significant 
differences between End.p53-WT and End.p53-KO mice are indicated within the graphs.  
 
As we did not observe a significant difference in Hif1α and Vegf protein levels at 8 and 20 
weeks time point, we analyzed mouse hearts at earlier time points (i.e. at 7 days after TAC). 
Hypertrophic hearts after 7 d TAC revealed elevated Hif1 protein levels in both genotypes 
and confirmed that the TAC-induced increase in Hif1 and Vegf expression was significantly 
more pronounced in mice lacking p53 in endothelial cells compared to their End.p53-WT 
counterparts (Figure 5.12. A-C).  
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Figure 5.12. Role of endothelial p53 for the cardiac and endothelial response to hypoxia after 7 days TAC. 
Western blot analysis of cardiac Hif1α and Vegf protein levels in End.p53-WT and End.p53-KO mice at 7 days 
time points after transverse aortic constriction (TAC) or sham operation. Representative membranes are shown 
in A. Representative findings of the quantitative analysis of n=3 independent experiments for Hif1α and Vegf 




Analysis of HCMECs, stable transduced with lentiviral vectors containing either scr or p53 
shRNA, followed by the exposure to CoCl2 confirmed that deletion of p53 in endothelial cells 
significantly enhanced Hif1 protein levels in response to (chemical) hypoxia (Figure 5.13. 
A and B). 
 
            A                                     B       
                                                                                       
 
Figure 5.13. Deletion of p53 in endothelial cells induces HIF1α expression when exposure to chemical 
hypoxia . A and B, Analysis of Hif1α protein levels in HCMECs after stable transfection with a lentiviral p53 
shRNA vector or scr shRNA (negative control) and exposure to chemical hypoxia (1 mM CoCl2 for 4 hours). 
Representative findings are shown in A, the results of the quantitative analysis of n=3 independent experiments 
in B. ***P<0.001.  
 
5.6. Deletion of p53 in Endothelial Cells Promotes Cardiac Angiogenesis 
 
To determine whether deletion of p53 and prevention of apoptotic cell death in endothelial 
cells is able to stabilize the cardiac microvasculature during experimental hypertrophy, the 
number of CD31-positive endothelial cells (Figure 5.14. A and B) and endothelial lectin-
perfused blood vessels (Figure 5.14. A and C) were quantified revealing a progressive 
decrease of functional (i.e. perfused) capillaries in hearts from End.p53-WT mice after TAC, 
whereas cardiac vascularization was significantly better in End.p53-KO vs. End.p53-WT 
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Figure 5.14. Cardiac vascularization in End.p53-WT and End.p53-KO mice. A, Representative pictures of 
CD31-immunopositive, isolectin B4-perfused capillaries in hearts of sham-operated and banded (8 and 20 
weeks after TAC) of End.p53-WT and End.p53-KO mice. Size bars represent 100 µm. B, Quantification of 
CD31-positive cells per mm². C, Quantification of the lectin-positive, i.e. perfused area. Size bars represent 100 
µm. The summary of the quantitative analysis in n=4-9 mice per group. *P<0.05 and ***P<0.001 vs. sham. 






5.7. Endothelial p53 Deletion Reduces Hypoxia in Hearts After TAC  
 
Expression of the hypoxia marker CAIX was increased in banded hearts of mice of both 
genotypes, but to a significantly lesser extent in End.p53-KO mice (P<0.001; Figure 5.15A 
and B) compared to the End.p53-WT mice suggesting that decrease in apoptosis and increase 
in vascularization decreases hypoxia in hypertrophic hearts of End.p53-KO mice. 
 
     A 
 
        B 
 
 
Figure 5.15. Expression of hypoxic marker in End.p53-WT and End.p53-KO mice. A, Immunostaining for 
CAIX to visualize hypoxia in hearts of End.p53-WT and End.p53-KO mice, sham-operated and banded (8 and 
20 weeks after TAC). Size bars represent 100 µm. B, The summary of the quantitative analysis in n=4-9 mice 
per group. *P<0.05 and ***P<0.001 vs. sham. Significant differences between End.p53-WT and End.p53-KO 
mice are indicated within the graphs. 
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5.8. Endothelial p53 Deletion Promotes Extra-Cardiac Angiogenesis  
 
To investigate the effect of endothelial p53 deletion in extra-cardiac angiogenesis, we 
induced unilateral hindlimb ischemia. Serial laser dopplar measurements at 14, 21 and 28 
days showed an improved reperfusion (Figure 5.16.A and B) and increased capillary density 
(Figure 5.16. C and D) within ischemic muscles from End.p53-KO compared to End.p53-WT 
mice. 
 
A      B 
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Figure 5.16. Effect of endothelial p53 deletion on neovascularization following hindlimb ischemia. A, 
Representative laser Doppler perfusion images before as well as on day 1 and 28 after unilateral hindlimb 
ischemia in End.p53-WT and End.p53-KO mice. B, Summarized findings after serial laser Doppler 
measurements of hindlimb perfusion in End.p53-WT (n=16) and End.p53-KO mice (n=14). **P<0.01 and 
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***P<0.001 vs. baseline; ###P<0.001 vs. End.p53-WT mice. C, Representative pictures of CD31-
immunopositive endothelial cells in cryosections through the gastrocnemic muscle. Cell nuclei were 
counterstained with DAPI. Size bars represent 100 µm. D, Quantitative analysis of the capillary density 28 days 
after ischemia induction (n=8-10 mice per group). **P<0.01 vs. the contralateral, uninjured leg. Significant 
differences between End.p53-WT and End.p53-KO mice are indicated within the graph.  
 
 
5.9. Inactivation/ Inhibition of p53 Activity Improves Angiogenic 
Properties of Endothelial Cells in vitro 
 
To study the effect of modulation of p53 activity in angiogenic properties of endothelial cells 
invitro, we used nonpeptidic small-molecule nutlin-3a (stabilizing p53 by inhibiting the 
mdm2p53 interaction) and pifithrin- (reducing p53 activity) and DMSO as a control. 
Western blot showed that 24 hourrs incubation of nutlin-3a induced the expression of p53 by 
activating its downstream effector p21, which was not seen in pifithrin- or DMSO treated 
cells (Fig 5.17. A). Immunostaining images (Fig 5.17. B) also shown that incubation of 
HCMEC's with nutlin-3a for 24 hrs enhanced p53 expression. 
 
A       B 
 
 







Figure 5.17. Effect of nutlin-3a and pifithrin- treatment on p53 modulation of endothelial cells in vitro. 
A, Representative Western blot membranes showing the expression of p53 or its downstream effector p21 after 
incubation of human cardiac microvascular endothelial cells (HCMECs) with either PBS (1), vehicle (DMSO; 
2), nutlin-3a (10 µM; 3) or pifithrin-α (20 µM; 4). Gapdh protein was used as internal control for equal protein 








Analysis using the spheroid angiogenesis assay revealed that pifithrin- treated endothelial 
cells were able to sprout more within 24 hours compared to nutlin-3a or DMSO treated cells 
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Figure 5.18. Effect of p53 modulation on the angiogenic properties of endothelial cells in vitro. A, 
Representative pictures of HCMEC spheroids after treatment with either DMSO, nutlin-3a or pifithrin-α. 
Magnification, X200. B and C, Summary of the quantitative and statistical analysis. The number of sprouts (B) 
or the total sprout length (C) per spheroid were calculated using ImagePro Plus image analysis software. 








5.10. Hearts from End.p53-KO Mice Revealed Lower Levels of Apoptosis 
and Improved Angiogenesis After Doxorubicin Treatment 
 
Doxorubicin, a cardiotoxic agent known to induce apoptosis via activation of p53, was used 
to treat endothelial cells resulting in higher p53 protein expression and increased levels of 
apoptosis (Figure 5.19. A, B). Doxorubicin was injected into End.p53-KO and WT mice as a 
single dose. Five days after treatment, significantly lower numbers of TUNEL-positive 
apoptotic cells (Figure 5.20. A-C) and higher amount of endothelial lectin-perfused blood 








Figure 5.19. p53 expression, apoptosis and angiogenesis after doxorubicin treatment in vitro and in vivo. 
A, p53 protein levels were examined in HCMECs after stimulation (for 24 hours) with PBS (1) or 0.5 µM 
doxorubicin (2) and compared to cells treated with DMSO (3) or 20 µM of the p53-inhibitor pifithrin-α (4) as 
negative control, or DMSO (5) or 10 µM of the p53 activator nutlin-3a (6) as positive control. B, Flow 
cytometry analysis of annexin V and propidium iodide (PI) expression revealed increased cell death in 
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Figure 5.20. Apoptosis and angiogenesis after doxorubicin treatment in vitro and in vivo. Representative 
images of 2 independent experiments are shown. A-C, Histological analysis of hearts from End.p53-WT (grey 
bars) and End.p53-KO mice (white bars) on day 5 after a single i.p. doxorubicin (DOX) injection revealed 
reduced numbers of apoptotic (i.e. TUNEL-positive). D, lectin-positive and lectin-negative cells as well as 
increased endothelial lectin perfusion in mice with endothelial cell-specific p53 deletion.  
 
 
5.11. Endothelial p53 Deletion Attenuates Pressure Overload-Induced 
Cardiac Fibrosis  
 
The effects of endothelial p53 deletion on cardiac remodeling after TAC was examined after 
staining with Masson’s trichrome. Fibrosis was negligible in sham-operated mice, multiple 
scattered foci of interstitial fibrosis were observed after TAC in End.p53-WT and to a  
significantly lesser extent in End.p53-KO mouse hearts, both at 8 and 20 weeks after TAC 
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Figure 5.21. Effect of endothelial p53 deletion on cardiac fibrosis. Representative images after MTC (A) 
staining to visualize fibrosis in hearts of End.p53-WT and End.p53-KO mice. Size bars represent 200 µm. B, 
Summary of the quantitative analysis in n=7-15 mice per group. **P<0.01 and ***P<0.001 vs. sham. 
Significant differences between End.p53-WT and End.p53-KO mice are indicated within the graphs. Significant 
differences between End.p53-WT and End.p53-KO mice are indicated within the graph. 
 
 
Picrosirius red staining confirmed reduced amounts of interstitial collagen in hearts of TAC-
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Figure 5.22. Effect of endothelial p53 deletion on accumulation of collagen after TAC. Representative 
images after sirius red (A) staining to visualize interstitial collagen accumulation in hearts of End.p53-WT and 
End.p53-KO mice. Size bars represent 200 µm. B, Summary of the quantitative analysis in n=7-15 mice per 
group. **P<0.01 and ***P<0.001 vs. sham. Significant differences between End.p53-WT and End.p53-KO 
mice are indicated within the graphs.  
 
Quantitative real time PCR analysis revealed lower cardiac mRNA levels of collagen type I 
alpha 1 (Col1a1) and vimentin in End.p53-KO compared to End.p53.WT mice 8 weeks after 
TAC (Figure 5.23.A). Moreover, increased expression of bone morphogenetic protein (Bmp)-
7 (Figure 5.23.B) and reduced levels of connective tissue growth factor (Ctgf) or 
plasminogen activator inhibitor (Pai)-1 (Figure 5.23.C) were detected in hearts of mice 
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lacking endothelial p53, suggesting that both reduced production and enhanced degradation 
of ECM proteins may be involved in the attenuated fibrosis observed in End.p53-KO mouse 
hearts. 
 
A                B 
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Figure 5.23. Effect of endothelial p53 deletion on cardiac fibrosis. E-G, Quantitative real time PCR analysis 
of the mRNA expression levels of ECM proteins and mesenchymal markers (A), or factors involved in ECM 
production (B) and degradation (C) in End.p53-WT and End.p53-KO mice hearts after TAC. Results were 
normalized to GAPDH and are expressed as -fold increase vs. sham-operated mice (set at 1; not shown). 






5.12. Deletion of p53 in Endothelial Cells Reduces Surrogate Markers of 
Endothelial-to-Mesenchymal Transition  
 
(Myo-)fibroblasts are a major source of ECM protein-producing cells in the heart and have 
been shown to originate, at least in part, from resident endothelial cells.
112
 In this regard, 
immunohistochemistry demonstrated that the number of cells immunopositive for both the 
mesenchymal marker FSP1 and the endothelial marker CD31 were reduced in hearts of 





Figure 5.24. Effect of endothelial p53 deletion on markers of EndMT and myofibroblast 





 cells in hearts of TAC-operated End.p53-WT and End.p53-KO mice (n=3-4 mice per group). Size 
bars represent 100 µm.  
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Similar findings were obtained after immunohistochemical detection of cells double-positive 
for CD31 and collagen type 1 (Figure 5.25A and B). 
  
         A 
          
 
 













Figure 5.25. Analysis of endothelial and mesenchymal marker expression in mouse hearts after TAC. A, 




 cells in 
hearts of End.p53-WT and End.p53-KO mice at 20 weeks after TAC surgery. *P<0.05 vs. sham. Significant 
differences between End.p53-WT and End.p53-KO mice are indicated within the graph.  
 
 
To test the hypothesis that reduced EndMT might have contributed to the observed 
differences in cardiac fibrosis, treatment of HCMECs with TGFβ1 in the presence or absence 
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of nutlin-3a or pifithrin-α revealed that stabilization of p53 promoted EndMT surrogate 
marker expression, whereas inhibition of p53 reduced it (Figure 5.26.A-C). 
 
A       B         C 
 
Figure 5.26. Effect of p53 activation or inhibition on TGFβ-induced endothelial-to-mesenchymal 
transition of human cardiac microvascular endothelial cells. A-C, Quantitative real time PCR analysis of the 
EndMT surrogate marker Snail (A), Slug (B) and Twist (C) mRNA expression in HCMECs after treatment with 
TGFβ, alone or in combination with nutlin-3a or pifithrin-α for 6 days. Similar findings were observed after 
treatment for 12 days (not shown). *P<0.05, **P<0.01 and ***P<0.001 vs. untreated cells; #P<0.05, ##P<0.01 
and ##P<0.001 vs. TGFβ-treated cells.  
 
 
Real time PCR analysis of whole hearts, TAC- or sham-operated (Figure 5.27.A-C) as well as 
of FACS-sorted CD31-immunopositive and -negative cells derived from banded hearts of 
either End.p53-WT or End.p53-KO mice (Figure 5.27.D-F) revealed lower mRNA 
expression levels of the transcription factors Snail, Slug and Twist in mice with endothelial 
p53 deletion. Treatment of HCMECs with TGFβ after stable transfection with scr or p53 
shRNA (Figure 5.27.G-I) also shown lower expression levels of Snail, Slug and Twist 








Figure 5.27. Effect of endothelial p53 deletion on markers of EndMT and myofibroblast 
transdifferentiation. Real time PCR analysis of whole mouse hearts (A-C; n=9 per group) or FACS-sorted 
CD31-positive or -negative cells (D-F; n=3 per group) from End.p53-KO (white bars) and End.p53-WT mice 
(grey bars) 8 weeks after TAC for Snail (A and D), Slug (B and E) and Twist (C and F) mRNA. ***P<0.001 vs. 
sham. Significant differences between End.p53-WT and End.p53-KO mice are indicated within the graphs. G-I, 
HCMECs were stable transfected with lentiviral p53-shRNA or negative control (scr) shRNA vector, treated 
with PBS or TGFβ1 (10 ng/mL) for 6 or 12 days and the expression of EndMT markers examined by real time 
PCR analysis. *P<0.05, **P<0.01 and ***P<0.001 vs. PBS-treated cells. Significant differences between p53 
shRNA and scr shRNA transfected cells are indicated within the graphs. 
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6.1. Major Findings of the Study 
 
In this study, we examined the importance and causal role of endothelial p53 expression for 
cardiac remodeling and the development of heart failure induced by chronic pressure 
overload in mice.  
 
Our main findings are that inducible deletion of p53 in endothelial cells of adult mice 
ameliorated pressure overload-induced cardiac fibrosis and attenuated the progressive LV 
dilation and systolic pump dysfunction present in End.WT-p53 mice, resulting in improved 
survival. Mechanistically, we provide experimental evidence that endothelial p53 deletion is 
associated with reduced numbers of apoptotic endothelial, but also non-endothelial cells 
(presumably cardiomyocytes, fibroblasts or smooth muscle cells) and increased cardiac 
Hif1 and Vegf levels, and prevents the rarefaction of capillary endothelial cells observed 
with developing heart failure thus improving cardiac perfusion and oxygenation. In addition 
to regulating genes involved in ECM production and turnover (in particular, Bmp7, Ctgf and 
Pai-1), p53 expression may also play a role in the phenotypic switching of endothelial cells 
into matrix-producing fibroblast-like cells. Thus, our data support the importance of 
endothelial cells during pressure overload cardiac remodeling and also suggest a direct link 
between endothelial cell p53 expression and cardiac fibrosis. 
 
6.2. Role of p53 in Myocardial Apoptosis and Heart Failure  
 
The tumor suppressor protein p53 is activated in response to a variety of cellular stress 
signals. DNA damage, but also oxidative stress, hypoxia or cytokine stimulation may induce 
apoptotic cell death via p53 and transcriptional activation of genes involved in cell cycle 
control and growth arrest.
112;138
A role for p53 in the pathogenesis of heart disease is 
supported by findings of increased apoptotic cell numbers and p53 protein levels in the 
myocardium of patients with advanced heart disease,
81 
correlating with the transition to heart 
failure.
80







 models of heart failure. Of note, quantitative analysis of TUNEL-positive 
cells in banded mouse hearts revealed 0.7% apoptotic cardiomyocytes and 1% apoptotic non-
87 
 
cardiomyocytes, half of which were identified as CD31-positive endothelial cells.
141
 
Activation of p53 may be causally involved in the development of heart failure. For example, 
mice with global p53 deficiency are characterized by increased cardiac angiogenesis and 
protection from acute myocardial infarction- or TAC-induced heart failure.
87
 Similar findings 
were observed in mice systemically treated with the synthetic p53 inhibitor pifithrin-.
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Overexpression of CHIP, an endogenous p53 inhibitor, prevented myocardial apoptosis and 
ameliorated ventricular remodeling after myocardial infarction.
142
 Global p53 deficiency
143
 as 
well as cardiomyocyte-specific expression of dominant-negative p53
144
 also protected against 
the cardiotoxic effects of doxorubicin, whereas a recent study in mice with cardiomyocyte-
specific p53 deletion did not observe any cardioprotection.
145
 In addition to the possibility 
that doxorubicin-induced apoptosis occurs in a p53-independent manner, the latter findings 
also suggest that p53 expression in other cell types (e.g. endothelial cells) may be more 
important, a hypothesis that is supported by the findings of the present study. Previous studies 
have shown that serum of heart failure patients induces endothelial cell apoptosis
146
 and that 
circulating levels of apoptotic microparticles provide independent prognostic information in 
patients with advanced heart failure.
147
 However, the cardioprotective effects of endothelial 
cell-specific p53 deletion have not been directly addressed so far. 
 
To investigate the cardioprotective effects of endothelial cell-specific p53 deletion in mice, 
we generated mice with inducible endothelial cell-specific p53 deletion (End.p53-KO mice). 
We hypothesised that stabilization of endothelial cells by preventing apoptosis of endothelial 
cells may improve vascularisation and can lead to better heart function during hypertrophic 
conditions. To investigate our hypothesis, cardiac hypertrophy was induced in End.p53-KO 
and End.p53-WT female mice by TAC surgery. We analyzed both groups at 8 and 20 weeks 
time point for cardiac hypertrophy and function. As we hypothesized, End.p53-KO mice 
expressed significantly lower levels of p53 and p21 mRNA and protein after TAC at 8 and 20 
weeks time points compared to wildtype mice (Figure 5.6 and 5.7). Although it is known that 
p53 knockout mice develop tumors with a high incidence,
148
 our endothelial-specific p53 
deletion mice did not show any signs of tumorigenesis, at least macroscopically and until 24 






6.3. Deletion of p53 in Endothelial Cells Exhibit Less Apoptosis and 
Hypoxia 
 
Endothelial cell apoptosis is a well-known anti-angiogenic mechanism. It occurs during 
vascular pruning, i.e. the removal of aberrant neovessels, and represents a vital step during 
secondary vascular network formation. Angiogenesis inhibitors have been shown to promote 
apoptosis,
149
 whereas angiogenic growth factors protect endothelial cells from programmed 
cell death.
150
 Overexpression of p53 was shown to inhibit endothelial differentiation and 
angiogenesis.
151
 Possible mechanisms by which p53 may limit angiogenesis include the 
transcriptional activation of angiogenesis inhibitors, such as collagen prolyl hydroxylase
152
 or 
increased production of Mmp2 or Mmp9 resulting in the release of anti-angiogenic factors, 
such as collagen-derived arresten.
153
 Interestingly, heat shock transcription factor-1 was 
found to protect hearts after TAC by suppressing p53 and upregulating Hif1 in endothelial 
cells.
154
 Recent paper has shown that during hypoxic condition p53 has contrasting roles in 
the regulation of Vegf expression. During the initial stages of acute hypoxia, p53 cooperate 
with Hif-1α to up regulate Vegf expression. On the other hand, after extended exposure to 
hypoxia or to genotoxic stress, p53 inhibit Vegf expression in a p21/retinoblastoma (Rb)-
dependent manner.
155
 In our study, we found that, End.p53-KO mice significantly reduced 
the apoptosis of endothelial and non endothelial cells (Figure.5.9 and 5.10) after TAC 
compared to the wildtype mice, suggesting that deletion of p53 in endothelial cells stabilise 
the endothelial cells by reducing the apoptosis and thereby accompanied the growing 
myocytes.  
 
Doxorubicin (Dox) is a member of Anthracycline (ANT) family of anticancer drugs. These 
drugs, when given to patients, may induce cardiotoxicity leading to cardiomyocyte apoptosis, 
myocardial fibrosis, and congestive heart failure. p53 plays a important role in Dox-induced 
apoptosis in cardiomyocytes and endothelial cells. Recently, it was reported that deletion of 
p53 in cardiomyocytes is not sufficient to block myocardial fibrosis and cardiomyocyte 
apoptosis.
145
 In our study, we showed that endothelial specific deletion of p53 significantly 
reduced apoptosis in endothelial and non endothelial cells and increased the capillary density 
(Figure 5.20. A-D) suggesting again that endothelial cell stabilization  or survival plays a 




6.4. Role of Hypoxia in Cardiac Hypertrophy and Angiogenesis 
 
Cardiac hypertrophy leads to myocardial ischemia, which is caused by the lack of perfusion 
and insufficient supply of nutrients. Lack of perfusion or blood supply leads to hypoxia and 
reduction in oxygen levels. Hypoxia can lead to cell death in chronic conditions. Hypoxia- 
inducing factors (HIFs) like Hif1 are stabilized under hypoxic conditions and induce 
adaptive angiogenesis by transcriptionally activating pro-angiogenic genes, such as Vegf. At 
the later stages of hypertrophy, p53 accumulates and interacts with Hif1 to disrupt the 
adaptive angiogenic activity, promoting its degradation and also by activating pro-apoptotic 
molecules like Bax, PUMA and Bcl2. 
87;156
 p53 and Hif1 both are involved in cell 
adaptation to various stress conditions, they are known to be involved in similar processes 





(Figure adapted from Obacz J et al Molecular Cancer 2013;12:93) 
 
Figure 6.1. HIF-1 and/or p53 regulated genes mediating adaptation to cellular stresses through activation 
of different pathways. 
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In our study, we found that endothelial cell-specific p53 deletion is associated with lower 
expression of surrogate markers of hypoxia (i.e. CAIX) and elevated Hif1 and Vegf levels 
in response to pressure overload in vivo or hypoxia in vitro. We found that Hif1 and Vegf 
are induced significantly higher in End.p53-KO mice during the initial stages of hypertrophy 
(at 7 day time point) compared to the wildtype mice after TAC (Figure 5.12). Our in vitro 
findings in p53 KO-HCMECs and normal HCMECs also confirmed our in vivo data by 
showing that when exposed to hypoxic state mimicked by CoCl2, deletion of p53 in 
endothelial cells significantly enhanced Hif1 protein levels (Figure 5.13) in response to 
(chemical) hypoxia compared to normal wildtype endothelial cells.  
 
6.5. Deletion of p53 Specifically in Endothelial Cells Enhances Cardiac and 
Extra-Cardiac Angiogenesis and Postponed Heart Failure after TAC 
  
Several studies have shown that the progression of cardiac hypertrophy towards heart failure 
is associated with rarefication of the cardiac microvasculature, which is then unable to 
support the increased oxygen and nutrient demands of the hypertrophied myocardium.
21-24 
Building on these previous findings, we could now show that deletion of p53 in endothelial 
cells prevents the reduction in cardiac capillary density after TAC resulting in enhanced 
perfusion of the hypertrophied heart and elevated Hif1 and Vegf levels. The anti-angiogenic 
effects of p53 could be confirmed in vitro as well as after induction of unilateral hindlimb 
ischemia in vivo. As we discussed earlier that deletion of p53 specifically in endothelial cells 
have significantly increased the Hif1 and Vegf levels after TAC, we looked at the 
angiogenesis in the heart tissue after 8 and 20 weeks after TAC. Angiogenesis was 
significantly increased in End.p53-KO mice at both the time points compared to wild type 
(Figure 5.14). Extracardiac angiogenesis or neovascularization was also significantly 
increased in End.p53-KO mice after unilateral hindlimb ischemia (Figure 5.16).  
 
Importantly, our findings also suggest that prevention of endothelial cell death and 
stabilization of cardiac capillaries may delay the progressive LV dilation and the decline of 
systolic pump function (Figure 5.4). In contrast to previous studies showing that 
augmentation of angiogenesis promotes myocardial hypertrophy even in the absence of an 
initiating stimulus,
25 
endothelial p53 deletion reduced the extent of cardiac hypertrophy at 
later time points (i.e. 20 weeks after TAC), as determined by wall thickness, heart weight or 
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cardiomyocyte area (Figure 5.5). Future studies will have to determine the pathways 
underlying the cross-talk between endothelial cells and cardiomyocytes during hypertrophy 
and how they are affected by p53. On the other hand, cardiac deletion of PUMA (p53-
upregulated modulator of apoptosis) was found to postpone heart failure after TAC and to 




6.6. Deletion of p53 Specifically in Endothelial Cells Attenuates TAC 
Induced Cardiac Fibrosis and Endothelial-Mesenchymal 
Transition (EndoMT) 
 
Hearts of End.p53-KO mice exhibited markedly reduced fibrosis (Figure 5.21) and expressed 
lower amounts of collagen type I (Figure 5.22, 5.25) and other mesenchymal markers (Figure 
5.24), which may have contributed to the preservation of cardiac pump function. Possible 
mechanisms underlying the reduced cardiac fibrosis in mice lacking p53 in endothelial cells 
may include indirect effects, such as improved cardiac perfusion limiting hypoxia and the 
death of adjacent cardiomyocytes. In this regard, reduced numbers of p53 (Figure 5.8), 
activated caspase-3 (Figure 5.9) and TUNEL-positive endothelial lectin-positive as well as 
endothelial lectin-negative cells (Figure 5.10) were observed in hearts of End.p53-KO mice. 
 
In addition, several genes involved in ECM synthesis and degradation are known to be 
directly regulated by p53 and may have acted in a paracrine manner on adjacent 
cardiomyocytes and/or fibroblasts.
91
 For example (Figure 5.23), End.p53-KO mouse hearts 
expressed significantly lower amounts of Ctgf, a major regulator of tissue fibrosis, and 
elevated Ctgf expression and increased liver fibrosis was recently reported in mice with 
hepatocyte-specific p53 activation.
159
 Moreover, the p53-regulated factors Pai-1 and Mmp9 
are not only involved in the proteolytic release of angiogenesis inhibitors, but also modulate 
ECM degradation. Of note, constitutive deletion of p53 in endothelial cells was recently 
reported to be associated with a worse outcome and more severe cardiac fibrosis in mice after 
total body irradiation,
145
 although differences in the type of injury may have contributed to 
this discrepancy.  
 




-double positive cells (Figure 5.24) or mRNA expression 
of surrogate markers of EndMT (i.e. Snail, Slug and Twist in Figure 5.27) in hearts of 
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End.p53-KO mice after TAC suggest that differences in EndMT may also have contributed to 
the observed protection against fibrosis mice lacking endothelial p53. Previous studies have 
shown that TGFβ-induced fibroblast activation and EndMT are significant contributors to 
myocardial fibrosis.
112
 Although cardiac levels of TGFβ, a major inducer of EndMT, did not 
differ between both genotypes, elevated levels of BMP7, previously shown to preserve the 
endothelial phenotype and to counteract TGFβ-induced organ fibrosis,
160
 were detected in 
hearts of End.p53-KO mice and might have contributed to our observations. Future studies 
will have to examine in more detail the exact role of p53 in EndMT regulation.  
 
Our results also suggest that modulating endothelial p53 expression may represent an 
interesting therapeutic target. In this regard, atorvastatin was found to restore ischemic limb 
loss in diabetes by activation of the Akt/mdm2 pathway and augmentation of p53 
degradation,
161
 and modulation of endothelial p53 may also underlie the beneficial effects of 
statins on markers of endothelial function and LV remodeling in heart failure patients.
162
 Our 
observations may be especially relevant in elderly subjects, a population at increased risk for 
heart failure, as previous studies could show that ageing is associated with elevated levels of 
the p53. For example, prolonged passaging (mimicking senescence) of human vein 
endothelial cells was associated with p53 accumulation,
163
 whereas mice with a truncated p53 
mutation resulting in p53 activation were protected against tumor formation, but exhibited an 



















Inducible, endothelial cell-specific deletion of p53 in adult mice 
 prevents endothelial and non-endothelial cell apoptosis,  
 induces Hif-1α and Vegf expression, 
 enhances cardiac and extra-cardiac new vessel formation, 
 reduces cardiac fibrosis and EndMT, 
 improves heart function and survival after TAC.  
 
In conclusion, our findings suggest that accumulation of p53 in endothelial cells contributes 
to the increased endothelial cell apoptosis and the rarefication of cardiac endothelial cells 
during cardiac hypertrophy and promotes the development of cardiac fibrosis and LV 
dysfunction through, at least in part, impaired cardiac perfusion and altered ECM remodeling. 
Attenuation of endothelial cell loss and apoptotic death and preservation of the cardiac 
microvasculature during pathologic hypertrophy may thus represent a promising approach to 
improve pressure overload-induced cardiac remodeling and to prevent the transition to heart 
failure. Moreover, our data also support the hypothesis of other investigators that apoptosis 
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